Method, compositions and applications of mechanosensitive channels in visual disorders, and other applications thereof
Patent Information
- Application Number
- JP2024002518
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-12-31
- Filing Date
- 2024-01-11
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for glaucoma, such as pharmacological and surgical interventions, have significant limitations and side effects, and there is a need for safe, effective, and long-lasting therapies that can reduce intraocular pressure and prevent optic nerve damage.
Utilization of mechanosensitive channels, specifically MscL proteins, as transgenic pressure regulators to act as tension-activated pressure release valves in mammalian cells, particularly trabecular meshwork cells, to manage intraocular pressure and facilitate aqueous humor drainage.
The method effectively reduces intraocular pressure, thereby preventing optic nerve damage and providing a potential long-lasting treatment for glaucoma without the side effects associated with existing therapies.
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
[Technical field]
[0001] (cross reference) This application is a continuation of U.S. Provisional Application No. 62 / 786,955, filed December 31, 2018. No. 60 / 339,933, filed on Oct. 23, 2007, which claims the benefit of, and which is incorporated herein by reference.
[0002] Some of the references may include publications, patents and patent applications, and are incorporated herein by reference in their entirety. Citation and / or discussion of such references does not constitute or imply any obligation to the reader to use, modify, or disclose this disclosure. Any such references are provided for clarity of explanation of the invention and are hereby incorporated by reference in their entirety. No admission is made that any of the material cited herein is "prior art" to the present invention. All references cited are incorporated herein by reference in their entireties, respectively. are incorporated by reference to the same extent as if each individual was incorporated by reference.
[0003] (Description of electronically submitted text files) The contents of any text fields submitted electronically herein are hereby incorporated by reference in their entirety. A computer readable format copy of the sequence listing (filename: HINENYE_SL_2019.txt, Recording date: 12 / 04 / 19, File size 9 kilobytes).
[0004] FIELD OF THEINVENTION The present invention relates generally to the development of novel mechanoreceptor channels in the treatment of different disorders of the eye and other organs. The present invention relates to novel methods, compositions, and uses. Specifically, the present invention relates to the treatment of glaucoma, dry eye, and and other diseases involving cells susceptible to mechanical or osmotic stress. Large Conductance Tank as a Transgenic Pressure Regulator and Alternative Outflow Actuator The present invention further relates to the utilization of mechanosensitive channels (MscL) with unique properties of Exploiting mechanosensitive channels for molecular transduction triggered by internal and external mechanical stimuli Regarding. [Background technology]
[0005] Cells in different organs in the body are involved in a variety of diseases, including neurological, cardiovascular, ophthalmic, and renal diseases. They are subjected to a range of mechanical and osmotic pressures that vary in different diseases. The small-conductance mechanosensitive channel (MscL) functions as an osmoregulatory mechanism and regulates low Protects cells from lysis during osmotic shock, but such channels are not found in mammalian cells. Does not exist.
[0006] As an example of a pressure-related disorder of interest, vision loss due to glaucoma is a common cause of death in the United States. 1 Vision in It is the second most common cause of glaucoma. It affects the livelihood, independence, and well-being of people with glaucoma and their families. Quality of life is destroyed by this widespread disease.
[0007] Glaucoma is defined as a group of eye disorders that are usually caused by elevated intraocular pressure (IOP). It causes damage to the optic nerve. The most common form of glaucoma is primary open-angle glaucoma (PO AG) and is characterized by poor drainage of aqueous humor through the traditional outflow pathway. In the ocular lens, aqueous humor passes through the trabecular meshwork (TM) into Schlemm's canal and is then drained into the episcleral veins. Several studies have demonstrated that trabecular meshwork (TM) cell processes and tandem meshwork in glaucomatous eyes. They characterize distinct changes in the fibrous structure, resulting in increased trabecular meshwork. (TM) Stiffness and aqueous tuft outflow resistance 2 is said to be explained.
[0008] The eye must maintain a healthy internal pressure to maintain its shape and function. To maintain an adequate intraocular pressure (IOP), the vitreous and aqueous humor must be continuously processed. Aqueous humor is involved in the structure, nutrition and hygiene of the tissues of the anterior chamber of the eye and its inflow and outflow Proper regulation of the outflow balance is crucial. Aqueous humor is produced by the ciliary body and is directed through the pupil. and is discharged either through the conventional outflow pathway or through the uveoscleral outflow pathway. In the conventional outflow pathway, aqueous humor flows through the trabecular meshwork (TM) into Schlemm's canal, then through Schlemm's canal. The blood flows out through a duct that branches off from the Lemm's canal into the episcleral blood vessels. Glaucoma usually occurs when intraocular pressure ( It is defined as a group of eye disorders that cause optic nerve damage due to elevated IOP. The primary means by which intraocular pressure (IOP) can be reduced are: i) reducing the production of aqueous humor; ii) to increase outflow through the uveoscleral outflow tract; iii) to reduce the or iv) to improve drainage through the pathways, or iv) to create alternative outflow pathways. There are means to do this.
[0009] Currently available pharmacological and surgical treatments for glaucoma have significant limitations and side effects. These undesirable side effects include systemic reactions to the drug, non-patient These include compliance, eye infections, failure of surgical equipment, and damage to other structures in the eye. In order to prevent the progression of the disease, most glaucoma cases require long-term treatment. For example, even after surgery, some glaucoma patients may experience Some people need to use eye drops every day for an indefinite period of time. The development of safe, effective, single-dose, long-lasting therapeutic agents for the treatment of It is desired.
[0010] Another option for treating uncontrolled glaucoma is surgery. The surgical procedure is trabeculectomy, in which the alternative outflow pathway is the sclera, Schlemm's The bleb is then molded from the conjunctival flap by removing the endothelial canal and a section of trabecular meshwork (TM). Other surgical methods include angioplasty, laser trabeculoplasty, and laser peripheral angioplasty. These include irisotomy, deep non-penetrating sclerotomy, and drainage device implantation. All surgeries As with any surgical procedure, there is a risk of infection, systemic side effects, and human error / instrument failure. Scarring is common after surgery, and scar tissue can block newly created drainage pathways. The cost, patient recovery time, and surgical results vary. Given these factors, new and innovative treatments for glaucoma are needed. It is clear that... Summary of the Invention
[0011] In order to address the above-mentioned problems, the present invention provides a method for the preparation of mammalian cells, including trabecular meshwork cells and epithelial cells. Heterologously expressed mechanosensitive channels as tension-activated pressure-relief valves in The present invention provides novel methods, compositions, and uses of the above-mentioned compounds.
[0012] In bacteria, the large conductance mechanosensitive channel (MscL) is a key regulator of osmoregulation. It functions as a phospholipase C (PcC) and protects cells from lysis during hypoosmotic shock. It directly senses tension in the lipid bilayer and instantly expands its large nonspecific pores in response. open to release cytoplasmic fluid, thereby relieving the increasing turgor pressure.
[0013] In one aspect of the invention, the present invention provides a method for the detection of viral infections in glaucomatous TM cells. We describe a method to use MscL as a transgenic pressure regulator to be delivered to mice. do.
[0014] In one embodiment of the present invention, the present invention relates to the MscL1 protein and its produced portion. A specific mutant synthetic polypeptide sequence is described, which sequence is expressed on mammalian cell membranes. When expressed, they can sense pressure changes, regulate intracellular pressure, or act as a barrier to the flow of fluids and therapeutic molecules. The MscL1 protein (SEQ ID NO: 1) regulates the transport of unspecified molecules.
[0015] In another embodiment of the invention, the present invention relates to one or more single mutations or one or more aberrant mutations. Combinations of mutations can be used to create proteins that regulate pressure sensitivity, pore size, gating, or dynamics. For example, the present invention relates to an agonist at position 113 of the MscL sequence (SEQ ID NO:1). At very low pressure, the I to L substitution at the amino acid residue corresponding to amino acid I It has been demonstrated that the effect of ultrasound on the sensitization of cells to ultrasound activation. hypersensitivity to β-lactamase (activated well below the threshold of MscS) and increased pressure sensitivity The top corresponds to the amino acid residue G at position 43 of MscL (SEQ ID NO: 1). This is achieved by substituting G with any of the other 19 naturally occurring amino acids.
[0016] In another embodiment, the present invention describes a protein, in which Msc L (SEQ ID NO: 1), The amino acid substitution from C to C improves pressure sensitivity and shortens the release time. Improved pressure sensitivity and shorter open time are at position(s) of MscL (SEQ ID NO:1) 131-133, 131-136, or 131-157, by deleting amino acid(s) This can also be achieved by
[0017] In another embodiment of the present invention, the K at position 122 can be replaced with any negative amino acid residue. Improving pressure sensitivity of protein (SEQ ID NO:1) by substituting charged amino acids Furthermore, the substitution of K at position 52 of MscL (SEQ ID NO: 1) is The substitution results in improved pressure sensitivity, shorter mean open time, and lower transition barrier. The amino acid residue corresponding to the amino acid Q at position 77 of MscL (SEQ ID NO: 1) In the present study, the amino acid substitution of Q to C, P, F, W, Y, or H in This results in improved stability, increased mean open time, and high transition barrier. From L to C in the amino acid residue corresponding to amino acid L at position 40 of column number 1) The amino acid substitutions in result in higher sensitivity to gating thresholds. do.
[0018] In another embodiment of the present invention, the present invention relates to the MscL2 protein (SEQ ID NO: 2) and The synthetic polypeptide sequences of the site-specific mutants generated are described below. When expressed on mammalian cell membranes, the protein senses pressure changes and regulates intracellular pressure. or modulate the transport of molecules, including but not limited to aqueous fluids and therapeutic molecules.
[0019] In another embodiment of the present invention, the present invention relates to the MscL3 protein and its derived fragments. The synthetic polypeptide sequences of specific mutants of the MscL3 protein (sequence Number 3) senses pressure changes and regulates intracellular pressure when expressed on mammalian cell membranes. or modulate the transport of molecules, including but not limited to aqueous fluids and therapeutic molecules.
[0020] In another embodiment of the present invention, the present invention relates to the MscL4 protein and its derived fragments. The present invention describes synthetic polypeptide sequences of mutants specific for the . When expressed, they sense pressure changes and regulate intracellular pressure or aqueous fluids and therapeutic molecules. The MscL4 protein (SEQ ID NO: 4) regulates the transport of molecules, including but not limited to.
[0021] In another embodiment of the invention, the present invention relates to one or more MscL proteins expressed in a cell. or a sequence of a concatemer of different MscL proteins or MscL monomers. The chimeras of sequence elements include signal peptides, endoplasmic reticulum (ER) transport signals, membrane transport signals, and one or more amino acid sequence motifs selected from the group consisting of an N-terminal Golgi export signal The present application describes a synthetic polypeptide sequence fused to a ribozyme. The signal transduction sequence also consists of MGRLLAL VVGAALVSSAC or MAVPARTCGASRPGPART, or any The sequences may also be selected from signal transduction peptide sequences.
[0022] In another embodiment of the present invention, the present invention provides a method for the preparation of bacterial mechanosensitive channels (MscL, MscS , MscK, MscG), plant mechanosensitive channel (MSL2-10), TRPV1-T RPV5 channels, Piezo channels, or their site-specific mutants , trabecular meshwork cells, epithelial cells in the body, which are subjected to mechanical pressure or osmotic pressure for therapeutic purposes; and other cells as tension-activated pressure relief valves. This section describes the method.
[0023] In another embodiment of the present invention, the MscL homologue strain is a bacterium, a fungus, a yeast, etc. Methods and compositions are described that include, but are not limited to,
[0024] In yet another embodiment, the present invention relates to a method for the preparation of a Mscl homologue strain comprising the steps of: , Bacillus subtilis, Mycobacterium leprae, Green sulfur photosynthetic bacteria, Thermophiles, Haemophilus influenzae, Erwinia Carotovora, Pseudomonas fluorescens, Clostridium perfringens, Staphylococcus aureus, Enterococcus faecalis, Lactobacillus lactis Bacillus subsp. malta, Caulobacter crescentus, Bacillus histolyticum, Fusobacter nucleatus subsp. Lotus japonicus rhizobia, Hemorrhagic septicemia bacteria, Soft rot bacteria, Pseudomonas aeruginosa, Salmonella typhimurium, Salmonella typhimurium, Pierce's disease bacteria, Corynebacterium glutamicum, Deinococcus radiodurans , Lactococcus lactis, Ralstonia solanacearum, Medicago sativa rhizobia, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus pyogenes, Leptomyces coelicolor, Methanosarcina acetivorans, Listeria inocula MscL derived from L. monocytogenes, etc., but not limited to The present application describes a composition that is not
[0025] In another embodiment, the present invention relates to a method for treating primary open angle glaucoma (POAG). The present invention provides a method for acting as an alternative outflow actuator for the
[0026] In another embodiment, the present invention provides that MscL function is conferred by the endothelial cells surrounding and / or endothelial cells of the TM. Supports natural paracytosis and transcytosis in the transcellular movement of aqueous humor , thereby reducing outflow resistance for the treatment of primary open angle glaucoma (POAG); A method for reducing intraocular pressure (IOP) is provided.
[0027] In yet another embodiment of the present invention, the present invention relates to a method for the production of mechanosensitive channels (e.g., MscL). ) is a viral vector (e.g., adenovirus, adeno-associated virus, lentivirus, ) or by non-viral methods, and the channel is provided with a matrix Gl By using a promoter such as the MGP promoter, In some, but not limited to, trabecular meshwork (TM) cells, glaucomatous eye damage They describe a method to act as a transgenic pressure regulator in cells. .
[0028] In another embodiment of the invention, the present invention provides a method for the delivery of a gene encoding a machine to a target tissue. Non-viral methods for delivering receptor channels (lipofection, nanoparticles / laser) This article describes a method for the delivery of
[0029] Another aspect of the present invention is that trabecular meshwork cells are ideal candidates for use as drainage valves. The reason why this is ideal is that the MscL is relatively small. It is a mono-oligomeric channel that does not require any associated tagging for assembly or function. This is because they do not require any protein or energy source.
[0030] In yet another embodiment, the present invention relates to mechanosensitive channels, their mutants, and generated portions thereof. The site-specific mutants may be used to treat intraocular pressures of, for example, greater than 20 mmHg, or between 120 and 20 Intra-arterial pressure of 0 mmHg (systolic) and 80 to 110 mmHg (diastolic), or 15 mm Physiological and non-physiological pressures selected from, but not limited to, intracranial pressures greater than 1000 Hz. The present invention provides a method for activating the
[0031] In a particular embodiment, the present invention relates to the introduction of MscL in cells of the trabecular meshwork (TM) and We demonstrate that the MscL bacterial channel functions in the foreign environment of the TM and in glaucoma patients. This leads to a decrease in intraocular pressure (IOP) in the
[0032] In yet another embodiment, the present invention relates to a method for the detection of meibomian gland endothelial cells, corneal epithelial cells, etc. , expression of mechanosensitive channels enhances the secretion of the aqueous phase of the tear film, regardless of the presence or absence of mechanical stimulation. and thus providing relief from dry eye disease (DED).
[0033] In yet another embodiment, the present invention provides a method for the production of MscL or The mutants, or site-specific mutants generated, were then subjected to osmotic stress or ultrasound. and applying extracellular stimuli including other mechanical actuations, but not limited to hydrodynamic pressure. The present invention provides a method that can be used to introduce molecules into cells.
[0034] In yet another embodiment, the present invention relates to a method for the production of MscL, or a polypeptide thereof, when expressed in a mammalian cell. Mutants, or site-specific mutants generated, can be used for extracellular The method provides that the application of a stimulus can be used to stimulate cells.
[0035] In a broader embodiment, the invention relates to MscL, or a variant or generated portion thereof. Specific mutants of the The microorganisms are delivered to and expressed in targeted mammalian cells in a promoter-specific manner. A biological channel (or channels) is a channel that is generated within the body and responds to a specific range of mechanical stimuli or osmotic stresses. under stress or using certain devices outside the body, including but not limited to ultrasound modulation The present invention provides compositions and methods that function in biological environments.
[0036] Any embodiment of the methods, devices, or compositions described herein may be used in any manner as described herein. It is contemplated that the present invention may be practiced with any other method, apparatus, or composition of matter. .
[0037] In one embodiment, the amino acid sequence is 75%, 85%, or 95% of SEQ ID NO: 1, 2, 3, 4, 5, or 6. %, 95%, or 100% identity to the sequence.
[0038] Further details relating to these and other embodiments are described below.
[0039] Other objects, features and advantages of the present invention will become apparent from the following detailed description. However, various changes and modifications within the spirit and scope of the present invention will become apparent to those skilled in the art from this detailed description. For purposes of clarity, the detailed description and specific examples illustrate specific embodiments of the invention. Although shown, it should be understood that they are given by way of illustration only.
[0040] The following drawings illustrate by way of example and not by way of limitation. For the sake of brevity and clarity, the given Not all features of a structure are always shown in every drawing in which the structure appears. The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The present invention is based on the detailed description of specific embodiments presented herein. , may be better understood by reference to one or more of these drawings.
[0041] Tables 1 to 6 show the different MscLs (MscL1, MscL2, MscL3, and MscL4). ) is shown. Different promoters (e.g., pMGP, CAG) are used as examples. It is used in the upstream region of the MscL sequence to target specific cells. [Brief description of the drawings]
[0042] [Figure 1A] A typical domain structure of the MscL gene construct with a 5' promoter sequence and a 3' fluorescent (mCherry) reporter sequence is shown. [Figure 1B] A typical circular DNA plasmid map is shown, showing the insertion of the MscL gene construct cloned between two restriction sites (BamH I and Sal I). [Figure 2A] A bright field image of HEK293 cells transfected with plasmid DNA containing the EcMscL-mCherry gene is shown. [Figure 2B] Red-filtered confocal fluorescence images of HEK293 cells transfected with plasmid DNA containing the EcMscL-mCherry gene are shown using 488 nm excitation and 560-660 nm emission filters. [Figure 2C] 1 shows stable current profiles of HEK293 cells expressing EcMscL before hypoosmotic shock. [Figure 2D] 1 shows the inward current profile of EcMscL-expressing HEK293 cells in response to hypo-osmotic shock (addition of 20% v / v water). [Figure 3A]A composite of bright field and red-filtered confocal fluorescence images of fetal rat trabecular meshwork cells transfected with plasmid DNA containing the EcMscL-mCherry gene is shown. [Figure 3B] Shown is a magnified confocal fluorescence (emission at 560-660 nm) image of two trabecular meshwork cells from fetal rats transfected with plasmid DNA containing the EcMscL-mCherry gene. [Figure 3C] 1 shows the inward current profile of EcMscL-expressing rat TM cells in response to hypo-osmotic shock (addition of approximately 20% v / v water). [Figure 3D] The peak current and open dwell time of EcMscL channels in TM cells and HEK cells are compared, respectively, N=5, AV±SD, *p<0.001. [Figure 4A] 1 shows bright field images of fetal rat trabecular meshwork cells transfected with plasmid DNA containing the EcMscL-mCherry gene. [Figure 4B] Confocal fluorescence (560-660 nm emission) images of fetal rat trabecular meshwork cells transfected with plasmid DNA containing the EcMscL-mCherry gene are shown. [Figure 4C] Confocal fluorescence (with excitation at 488 nm and emission at 505-525 nm) images of fetal rat trabecular meshwork cells transfected with plasmid DNA containing the EcMscL-mCherry gene are shown. [Figure 4D] Brightfield images of fetal rat trabecular meshwork cells transfected with plasmid DNA containing the EcMscL-mCherry gene are shown using approximately 1 U / mL of Alexa Fluor™ 488 phalloidin dye. [Figure 4E] Confocal fluorescence (with excitation at 488 nm and emission at 505-525 nm) images using approximately 1 U / mL of Alexa Fluor™ 488 phalloidin dye are shown of fetal rat trabecular meshwork cells transfected with plasmid DNA containing the EcMscL-mCherry gene. [Figure 4F]Confocal fluorescence (using 488 nm excitation and 505-525 nm emission) images are shown of fetal rat trabecular meshwork cells transfected with plasmid DNA containing the EcMscL-mCherry gene, with approximately 2 U / mL of Alexa Fluor™ 488 phalloidin dye. [Figure 4G] Brightfield images of fetal rat trabecular meshwork cells transfected with plasmid DNA containing the EcMscL-mCherry gene using approximately 2 U / mL Alexa Fluor™ 488 phalloidin dye are shown 15 minutes after hypoosmotic shock (addition of 20% v / v water), with the control (not expressing EcMscL-mCherry) indicated by the arrow. [Figure 4H] Confocal fluorescence (with 488 nm excitation and 505-525 nm emission) images of fetal rat trabecular meshwork cells transfected with plasmid DNA containing the EcMscL-mCherry gene using approximately 2 U / mL Alexa Fluor™ 488 phalloidin dye, 7.5 minutes after hypoosmotic shock (addition of 20% v / v water), using 488 nm excitation and 505-525 nm emission filters. [Figure 4I] Confocal images of fetal rat trabecular meshwork cells transfected with plasmid DNA containing the EcMscL-mCherry gene, using approximately 2 U / mL Alexa Fluor™ 488 phalloidin dye through a green filter, 15 minutes after hypo-osmotic shock (addition of 20% v / v water), using a 488 nm excitation and 505-525 nm emission filter are shown. [Figure 4J] The dynamics of green fluorescence intensity in cells is shown, demonstrating that only EcMscL expressing cells take up the dye, while non-transfected cells remain dark. [Figure 5A] 1 shows the principle of response of MscL-sensitized cells to membrane tension / membrane deformation induced by mechanical force stimulation. [Figure 5B]The principle of controlling intraocular pressure by sensitizing trabecular meshwork cells with MscL is demonstrated. [Figure 6A] The MGP-EcMscL-mCherry gene packaged in AAV8 virus was delivered to the anterior chamber of the mouse eye by intracameral injection and expressed in the trabecular meshwork (TM). Confocal images of the iridocorneal region of a cross section of an eye treated with the MGP-EcMscL-mCherry gene packaged in AAV8 virus, stained with DAPI dye (blue fluorescence), show cells in the cornea and TM. [Figure 6B] Confocal images of cross sections stained with anti-mCherry antibody (red fluorescence) from eyes treated with AAV8 virus-packaged MGP-EcMscL-mCherry genes. The strong red fluorescence of the reporter (mCherry) seen in the TM indicates successful TM-targeted expression of EcMscL-mCherry. [Figure 6C] Figure 1 shows increased IOP in mice treated with 0.1% dexamethasone (DEX) applied topically three times daily (N=7). [Figure 6D] Figure 1 shows the reduction in intraocular pressure (IOP) in the right eye (OD) 3 weeks after intracameral injection of virally loaded EcMscL into the TM-targeted right eye (OD). (N=4). Mean values ± standard deviation are shown. [Figure 6E] Figure 1 shows the reduction in intraocular pressure (IOP) in the contralateral eye = left eye (OS) 3 weeks after intracameral injection of virus-loaded EcMscL in the right eye (N=4). Mean values ± standard deviation are shown. [Figure 7] Confocal images of flat-mounted mouse retina transfected with EcMscL-double mutant (I113L / I70E, SEQ ID NO:5) by intravitreal injection and nano-enhanced optical delivery (NOD), a type of non-viral (laser-assisted) transfection method. Laser irradiation was performed in a rectangular area (marked by the dotted border), so that the retina immunostained with anti-mCherry antibody shows red fluorescence in the transfected area. [Figure 8A]MGGP-EcMscL (SEQ ID NO: 1)-mCherry gene was packaged in AAV8 virus and delivered to mice via lateral tail vein lateral injection, and expressed in the brain region. Shown is a confocal image of a part of the mouse brain transfected with EcMscL-mCherry in the cerebellum region, stained with DAPI (blue fluorescence). Scale bar is 20 micrometers. [Figure 8B] Confocal images stained with anti-mCherry antibody (red fluorescence) showing transfection and EcMscL expression at the edge of the cerebellum. Arrows indicate the transfected area. [Figure 8C] Confocal images of sections of EcMscL-mCherry transfected mouse brains in the pons and medulla oblongata regions stained with DAPI (blue fluorescence) are shown. [Figure 8D] Antibody regions showing transfection and EcMscL expression in the pons and medulla oblongata regions are shown. [Figure 9A] Confocal images of reporter (mCherry) fluorescently transfected HEK293 cells expressing MtMscL-mCherry (see SEQ ID NO:2), showing plasma membrane localization of protein expression. [Figure 9B] 1 shows the inward current profile of HEK293 cells expressing patch-type MtMscL after hypo-osmotic shock (addition of 20% v / v water). [Figure 9C] Figure 1 shows an overlay of red and green filtered confocal images of HEK293 cells transfected with MtMscL-mCherry genes in a solution containing a membrane impermeable dye (Alexa Fluor™ 488 carboxylic acid succinimidyl ester, green), 25 min after hypo-osmotic shock. The image shows that uptake of the dye (green fluorescence) is only in MtMscL expressing cells. [Figure 9D] The dynamics of green fluorescence intensity in cells is shown, with MtMscL-expressing cells (e.g., cell 1, cell 2, cell 3) shown to take up the dye, while non-transfected cells remain dark. [Figure 10A] 1 shows confocal images of HEK293 cells transfected with EcMscL(I113L / I70E)-mCherry gene (see SEQ ID NO:5) in a solution containing the membrane impermeable dye Alexa Fluor™ 488 carboxylic acid succinimidyl ester. [Figure 10B] 1 shows the inward current profile of HEK293 cells expressing patched EcMscL(I113L / I70E) in response to hypo-osmotic shock (addition of 20% v / v water). [Figure 10C] The dynamics of green fluorescence intensity of a membrane-impermeable dye (Alexa Fluor™ 488 carboxylic acid succinimidyl ester) in cells is shown, and only EcMscL (I113L / I70E)-expressing cells (e.g., cell 1, cell 2, and cell 3) are shown to have taken up the dye, while non-transfected cells remain dark. [Figure 11A] 1 shows an overlay of red and green filtered confocal images of HEK293 cells transfected with the VcMscL-mCherry gene (see SEQ ID NO:4) in a solution containing a membrane impermeable dye (Alexa Fluor™ 488 carboxylic acid succinimidyl ester). [Figure 11B] The dynamics of green fluorescence intensity in cells is shown, demonstrating that only VcMscL-expressing cells (e.g., cell 1, cell 2, cell 3, and cell 4) have taken up the membrane-impermeable dye Alexa Fluor™ 488 carboxylic acid succinimidyl ester, while untransfected cells remain dark. [Figure 12A] Confocal images of anti-mCherry antibody immunostained blood vessels in mice are shown. [Figure 12B] Confocal images of anti-mCherry antibody immunostained blood vessels in mice transfected with EcMscL-double mutant (I113L / I70E, SEQ ID NO:5), showing red fluorescence in the vessel walls. [Figure 13]Figure 1 shows the extracellular potential of HEK293 cells expressing EcMscL grown on multi-electrode array (MEA) Petri dishes in response to hypo-osmotic shock (addition of 20% v / v water). A burst of spikes can be seen in the signal between 13 and 14.5 seconds, indicating vigorous EcMscL channel activity. [Figure 14A] 1 shows the extracellular potential of HEK293 cells (-VE control) grown on multi-electrode array (MEA) Petri dishes. [Figure 14B] Figure 1 shows EcMscL channel activity induced by ultrasound stimulation (pulse width: 250 ms, repetition rate: 2 Hz, frequency: 1.1 MHz) in HEK293 cells expressing EcMscL, measured by extracellular potential using a multielectrode array (MEA) Petri dish. [Figure 15] Confocal images of mouse corneas transfected with EcMscL-mCherry via AAV8-based transduction, with reporter-mCherry expression indicated by red fluorescence. [Figure 16A] Confocal images of mouse hearts transfected with EcMscL-mCherry via AAV-based transduction, with reporter-mCherry expression indicated by red fluorescence. [Figure 16B] Confocal images of mouse kidneys transfected with EcMscL-mCherry via AAV-based transduction, with reporter-mCherry expression indicated by red fluorescence. [Figure 16C] Confocal images of mouse liver transfected with EcMscL-mCherry via AAV-based transduction, with reporter-mCherry expression indicated by red fluorescence. [Figure 16D] Confocal images of mouse lungs transfected with EcMscL-mCherry via AAV-based transduction, with reporter-mCherry expression indicated by red fluorescence. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0043] Glaucoma is often asymptomatic at onset, and sufferers do not realize they have a problem until later. This is why glaucoma is known as the "thief of vision." Glaucoma is more prevalent among the elderly, African Americans, diabetics, and people with the same disease. Although it is more prevalent among people with family members who have There is no particular group of people in the target population who will not develop glaucoma. It is extremely difficult, and the damage done to the optic nerve as a result of bilateral glaucoma is irreversible. Developing a safe, effective, one-time treatment for glaucoma that has a long-lasting effect is It will improve the lives of many glaucoma patients and revolutionize the way glaucoma is treated. be.
[0044] Glaucoma usually occurs due to a rise in intraocular pressure (IOP). It is defined as a group of eye disorders that cause optic nerve damage due to elevated intraocular pressure (I To maintain the OP, the vitreous and aqueous humor must be continuously treated. In patients with glaucoma, there is a restriction in the flow of aqueous humor through the trabecular meshwork, which is connected to the Schlemm's canal and It blocks drainage to the episcleral blood vessels and results in an increase in intraocular pressure (IOP). The main means by which P can be reduced are as follows: i) reducing the production of aqueous humor. ii) to increase outflow through the uveoscleral outflow pathway; and iii) to reduce outflow through the conventional pathway. or iv) improving drainage through the ureter, or iv) creating alternative outflow pathways. exist.
[0045] Current pharmaceutical and surgical therapies for treating glaucoma have significant limitations and side effects. The pharmaceutical approach involves the delivery of drugs via daily eye drops, ointment application, or oral tablet administration. Besides the unwanted side effects, these patient-dependent treatment protocols also have the potential to There is a major problem of poor compliance by the users. To achieve this, researchers developed a non-invasive technique that slowly releases drugs into the eye over a period of several months. However, many patients have difficulty managing their drug response and disease. As their conditions change over time, the medications and dosing regimens applied to them may change. You will constantly need to make adjustments.
[0046] Surgical options include trabeculectomy, canaloplasty, laser trabeculoplasty, and laser endoscopic trabeculoplasty. These include laser peripheral irisotomy, deep non-penetrating sclerotomy, and drainage device implantation. As with surgery, there are risks of infection, systemic side effects, and human error / instrument failure. Scarring is common after surgery at the site of the ulcer, and scar tissue can block the newly created drainage pathways. The cost, patient recovery time, and surgical results vary. Given the current situation, new and innovative treatments for glaucoma are needed. It is clear what is being said.
[0047] As an alternative to surgical and pharmacological treatments, the present invention provides a novel and specific method for treating glaucoma. The present invention describes a method and composition for reducing intraocular pressure (IOP) and thereby preventing glaucoma. A method for preventing continued optic nerve damage in cataract patients is provided.
[0048] It is estimated that 80-90% of aqueous humor drains through the conventional outflow pathway. In addition, primary open-angle glaucoma (POAG) is often accompanied by elevated intraocular pressure (IOP). Research has also shown that increased resistance to outflow through TM is associated with Therefore, the existing ones that deal with improving runoff through traditional runoff channels are There are few existing glaucoma surgical procedures and the FDA recently approved glaucoma treatment There is only one drug for treating cataracts 3、4 It is striking to find that Instead, many surgeries and drugs reduce the production of aqueous humor (e.g., beta-blockers) or or increase uveoscleral outflow (e.g., prostaglandin analogs) I am trying one of the following.
[0049] In one embodiment, the present invention utilizes an extrinsic polymer pressure sensor and an outflow actuator. and a method for regulating intraocular pressure (IOP) by increasing outflow through the TM. and compositions are provided.
[0050] In another embodiment, the present invention provides an extrinsic polymeric pressure sensor that provides a large conductance function. Methods and compositions are provided that relate to mechanosensitive channels and variants thereof.
[0051] In yet another embodiment, the MscL proteins and portions thereof of SEQ ID NOs: 1-4 are The resulting mutants, when expressed on the cell membrane, sense pressure changes and respond to intracellular pressure or cell division. The present invention regulates the transport of molecules (including but not limited to aqueous fluids and therapeutic molecules).
[0052] In another embodiment of the present invention, the MscL homologue strain is a bacterium, a fungus, a yeast, Methods and compositions are described that include, but are not limited to,
[0053] In yet another embodiment, the present invention relates to a method for the preparation of a MscL homologue strain comprising the steps of: , Bacillus subtilis, Mycobacterium leprae, Green sulfur photosynthetic bacteria, Thermophiles, Haemophilus influenzae, Erwinia Carotovora, Pseudomonas fluorescens, Clostridium perfringens, Staphylococcus aureus, Enterococcus faecalis, Lactobacillus lactis Bacillus subsp. malta, Caulobacter crescentus, Bacillus histolyticum, Fusobacter nucleatus subsp. Lotus japonicus rhizobia, Hemorrhagic septicemia bacteria, Soft rot bacteria, Pseudomonas aeruginosa, Salmonella typhimurium, Salmonella typhimurium, Pierce's disease bacteria, Corynebacterium glutamicum, Deinococcus radiodurans , Lactococcus lactis, Ralstonia solanacearum, Medicago sativa rhizobia, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus pyogenes, Leptomyces coelicolor, Methanosarcina acetivorans, Listeria inocula MscL derived from L. monocytogenes, etc., but not limited to The present application describes a composition that is not
[0054] In yet another embodiment, the present disclosure also provides a method for the preparation of a medicament for the treatment of a mammalian cell comprising administering to said mammalian cell .... Addition / deletion, truncation, or substitution of one or more amino acid sequence motifs Thus, in some embodiments, the present invention provides a method for the preparation of a modified MscL protein expressed in The MscL protein expressed in cells contains a signal peptide, an endoplasmic reticulum (ER) transport signal. one or more selected from the group consisting of a nucleotide sequence, a membrane transport signal, and an N-terminal Golgi transport signal. The MscL protein is fused to the amino acid sequence motif above. One or more amino acid sequence motifs that enhance transport are inserted into the N-terminus, C-terminus, or The fusion can be to either the N-terminus, or to both the N-terminus and C-terminus.
[0055] Another aspect of the present invention is directed to the large conductance mechanosensitive channel (MscL). describes viral delivery of a transgene encoding a chromosome-specific marker to TM cells, Once the deoxyribonucleic acid is translated and incorporated into the cell membrane, the channel is activated in response to increases in intraocular pressure (IOP). It is possible to facilitate the movement of fluid out of the cell.
[0056] In one embodiment, the present invention provides a method for treating a vascular endothelial disorder in which a portion of the secreted cellular fluid enters Schlemm's canal and further into the vascular system. The present invention provides methods and compositions for draining and thereby reducing the volume of fluid within the eye. Ultimately, this reduction in fluid volume results in a reduction in intraocular pressure (IOP).
[0057] Previous studies have shown that inhibition of TM cell contractility induces cell shape changes, which This creates more intercellular space, resulting in increased flow of aqueous humor (AH) through the TM. Another aspect of the present invention is that activation of MscL also The primary benefit of MscL is the increased cell proliferation that occurs as a result of its activation. The reduction in the size of the cornea creates more intercellular space, which inevitably increases the paracellular transport of aqueous humor. Because.
[0058] In another embodiment, the present invention relates to a method for the treatment of inflammatory bowel disease caused by a shift in cellular equilibrium following MscL activation. The cellular recovery process that occurs during this process may affect several signaling pathways that may affect TM cell function. Methods and compositions are provided that can trigger the cascade. For example, in bacteria, heat shock Expression of MscL protein is increased after MscL gating during hypoosmotic shock At the same time, mutant myosin (primary open-angle glaucoma in some patients) has been shown to be Glaucoma TM cells expressing glaucoma-associated glaucoma (the cause of POAG) have increased outflow resistance, but Co-expression of protein folding chaperones (including heat shock proteins) improved efflux. The above improvements are due to the fact that the chaperones are not suddenly changed. Preventing the aggregation of heterologous myocilin-induced proteins (thereby improving cell function) With these two studies in mind, the Msc. L activation induces heat shock protein β in mutant myocilin-induced glaucomatous TM cells When expression is triggered, aqueous humor (AH) outflow should also be facilitated (improved). It can be assumed that
[0059] In yet another embodiment, the present invention relates to a method for treating inflammatory bowel disease, comprising administering to a subject an effective amount of MscL, the method comprising administering to the subject a therapeutically ... Cellular processes that result in cell shrinkage and increased intercellular space and can increase protective genes The present invention provides methods and compositions for triggering a process.
[0060] Another aspect of the invention is that it does not require a partner or energy source to perform its function. In this paper, we describe MscL as an autonomous sensor and actuator. MscL is essentially , senses the tension in the lipid bilayer and opens and closes the gate in direct response to this mechanical stimulus.
[0061] In a preferred embodiment, the present invention provides an adeno-associated virus (AAV) compatible plasmid D The NA construct encodes the MSCL gene and a TM-specific promoter, and is expressed in TM cells. Methods and compositions are described that result in the expression of MscL in Escherichia coli, preferably Escherichia coli MscL. L(EcMscL) is selected because EcMscL is the most robust and It is a well-characterized MscL homologue. The MscL gene was recovered from the BL21(DE3) E. coli strain encoding the MscL gene and transformed with mammalian cells. The gene was codon optimized for expression in cells and placed under the control of a TM-specific promoter. Several studies have shown that in the eye, matrix Gla protein (MGP) is involved in the TM It is preferentially expressed in cells and its promoter sequence can be used to target gene expression. It is located on chromosome 12 at 14886367-14885792. The MGP promoter sequence (pMGP) was cloned using the primers of Linton et al. (2005). The DNA was identified using the GRCh38.p12 gene and aligned against the reverse complement of the human genome. The resulting 576 bp promoter sequence was inserted into the 5' end of the EcMscL gene. The fused fluorescent reporter served as a visual marker for gene expression and membrane localization. EcMscL is a homo-oligomer and has been shown to function post-translationally. The fluorescent proteins were strictly selected because they needed to assemble into complexes. It was necessary to avoid any interactions that could cause confusion. To achieve this, the monomeric fluorescent protein M-Cherry was fused to MscL at the C-terminus. Later, the pAAV-MCS plasmid backbone was used for viral transfer of genes into HTM. It is a notable base because it has been used successfully.
[0062] In another embodiment, the present invention relates to a method for the preparation of primary cultured TM cells by lipofection. The cells were transfected with MscL plasmid DNA and protein expression and localization were analyzed by epifluorescence colocalization. They describe a method in which cells are assayed by confocal microscopy. They also describe a method in which cells are assayed by transmission microscopy. to see if there are any changes in their morphology or growth cycle. Protein localization assay using anti-mCherry (reporter) antibody was performed using Western blotting. This was done using the blotting method.
[0063] In yet another embodiment, the present invention provides a method for the preparation of a method for the preparation of a TM cell membrane comprising the steps of: The retention of β-amyloides in membrane patches excised from the surface of EcMscL-expressing HTM cells was confirmed. In this paper, we provide a method for measuring channel gating through electrophysiological recordings. Mechanical stimulation is achieved by applying suction to the patch clamp pipette to generate negative pressure. He led me to believe that.
[0064] In another embodiment, the present invention relates to mechanoreceptor agonists in other cells of the eye for the treatment of glaucoma. The present invention provides a method and composition for expressing a Schlegel channel in ocular cells. Tube cells, retinal ganglion cells, glial cells, ciliary cells, corneal cells, bipolar cells, and photoreceptors In this role, mechanosensitive channels are involved in the regulation of endothelial function, including but not limited to, somatic cells. It acts as an osmoregulatory mechanism, influencing the production and composition of aqueous and vitreous humor and responding to compressive stresses. It may protect power, supplement neural activity, and perform other functions as mentioned above.
[0065] In another aspect of the present invention, the methods and compositions of mechanosensitive channels include any known mechanosensitive channel. These refer to channels and proteins that are activated by stretch or are activated by tension, such as MscS, MscK, and M scG, MSL2-MSL10, MCA, TPK, piezo channel, TRPV1-TRP V5, OSM-9, Mys1, Mys2, and MSC1. I can't.
[0066] Another aspect of the present invention is directed to bacterial mechanosensitive channels (MscL, MscS, MscK ... cG), plant mechanosensitive channels (MSL2-10), TRPV1-TRPV5 channels Heterologous, piezochannels, or their site-specific mutants, Mechanosensitive channels expressed in the arterial system in the treatment and prevention of hypotension and hypertension. In epithelial cells, it serves as an osmoregulatory mechanism that is activated by internal or external mechanical stimuli This document describes how the
[0067] In another embodiment of the present invention, the present invention provides a method for the preparation of bacterial mechanosensitive channels (MscL, MscS , MscK, MscG), plant mechanosensitive channels (MSL2-10), TRPV1-T RPV5 channels, Piezo channels, or their site-specific mutants Mechanosensitive channels such as these may be useful in treating hypertension and hypotension-related diseases when expressed in hematopoietic stem cells. It acts as an osmoregulatory mechanism and provides resistance to osmotic shock in the treatment and prevention of diseases. The authors describe a method for producing red blood cells having
[0068] In another embodiment of the present invention, the present invention provides a method for the preparation of bacterial mechanosensitive channels (MscL, MscS , MscK, MscG), plant mechanosensitive channels (MSL2-10), TRPV1-T RPV5 channels, Piezo channels, or their site-specific mutants Heterologously expressed mechanosensitive channels such as In prevention, osmotic pressure in the renal system is activated by internal or external mechanical stimuli. The method is described as being used as a regulating or diuretic mechanism.
[0069] Another aspect of the present invention is directed to bacterial mechanosensitive channels (MscL, MscS, MscK ... cG), plant mechanosensitive channels (MSL2-10), TRPV1-TRPV5 channels Heterologously expressing a piezo channel or a mutant thereof specific to the site of its production. The mechanoreceptor channels are useful in the treatment and prevention of gallstones in the liver, gallbladder, or bile duct of the hepatic system. In cells, it serves as a bile regulatory mechanism activated by internal or external mechanical stimuli This document describes how the method is implemented.
[0070] Another aspect of the present invention is directed to bacterial mechanosensitive channels (MscL, MscS, MscK ... cG), plant mechanosensitive channels (MSL2-10), TRPV1-TRPV5 channels Heterologous, piezochannels, or their site-specific mutants, The mechanoreceptor channels expressed in the endothelial cells may be useful in treating and preventing edema by detecting internal or external mechanical As a stimulus-activated osmoregulatory mechanism and as an alternative efflux / influx for fluids These diseases include passive subretinal floating for ocular edema, cystoid macular edema, lymphedema, peripheral edema, pulmonary edema, and foot edema, and osteoarthritis. Symptoms include, but are not limited to, swelling of the knee and other joints.
[0071] In another embodiment of the present invention, the present invention provides a method for the preparation of bacterial mechanosensitive channels (MscL, MscS , MscK, MscG), plant mechanosensitive channels (MSL2-10), TRPV1-T RPV5 channels, Piezo channels, or their site-specific mutants Such heterologously expressed mechanoreceptor channels are involved in the reproductive system and cause erectile dysfunction, Internally or in the treatment and prevention of vaginal dryness, benign prostatic hyperplasia, and polycystic ovary syndrome. As an osmoregulatory mechanism activated by external mechanical stimuli and as an alternative source of fluid This paper describes how the ion exchange membrane can be used as a suitable inflow / outflow pathway.
[0072] In yet another embodiment of the present invention, the present invention provides a bacterial mechanosensitive channel (MscL, MscL). cS, MscK, MscG), plant mechanosensitive channels (MSL2-10), TRPV1 ~TRPV5 channels, Piezo channels, or their site-specific mutations Heterologously expressed mechanosensitive channels, such as chromosome 1, may be used to treat a variety of conditions, including sweat gland dysfunction. Permeation therapy activated by internal or external mechanical stimulation in the treatment of any skin-related disease It is used as a pressure regulation mechanism and as an alternative inflow / outflow pathway for fluids. It describes the law.
[0073] In yet another embodiment of the present invention, the present invention provides a bacterial mechanosensitive channel (MscL, MscL). cS, MscK, MscG), plant mechanosensitive channels (MSL2-10), TRPV1 ~TRPV5 channels, Piezo channels, or their site-specific mutations Heterologously expressed mechanosensitive channels, such as endothelial cells, may be useful in the treatment of idiopathic intracranial hypertension. In the endothelium, as an osmoregulatory mechanism activated by internal or external mechanical stimuli, and as a mechanism for the regulation of circulatory The method describes a method in which the endothelial cell is used as an alternative inflow / outflow pathway for the body.
[0074] In another embodiment of the present invention, the present invention provides a method for the preparation of bacterial mechanosensitive channels (MscL, MscS , MscK, MscG), plant mechanosensitive channels (MSL2-10), TRPV1-T RPV5 channels, Piezo channels, or their site-specific mutants Heterologously expressed mechanosensitive channels such as these may be useful therapeutic options for diseases, including cancer. Activated by internal or external mechanical stimuli for enhanced drug delivery to enhance They describe a method in which the endothelial cell can be used as an intracellular transmembrane port for transport.
[0075] Another aspect of the present invention is the binding of specific receptors, such as the epidermal growth factor receptor (EGFR), or pH-dependent Constitutive expression of mechanosensitive channels in cancer cells targeted by the cell wall By bioengineering open, "leaky" channels or by over-inserting the channels, They describe a method to promote cell death by stimulating
[0076] Another aspect of the present invention is directed to bacterial mechanosensitive channels (MscL, MscS, MscK ... cG), plant mechanosensitive channels (MSL2-10), TRPV1-TRPV5 channels Heterologous, piezochannels, or their site-specific mutants, Mechanosensitive channels expressed in the brain have been shown to be effective in treating, for example, pain, epilepsy, stroke, and cardiovascular disease. The treatment of various diseases, including but not limited to neurological diseases such as muscular dystrophies They can be used to stimulate cells, including nerve cells, cardiac cells, and muscle cells, for therapeutic and prophylactic purposes. It describes the manner in which it is used.
[0077] In another embodiment of the present invention, the present invention provides a method for the preparation of bacterial mechanosensitive channels (MscL, MscS , MscK, MscG), plant mechanosensitive channels (MSL2-10), TRPV1-T RPV5 channels, Piezo channels, or their site-specific mutants Heterologously expressed mechanosensitive channels such as It is activated by mechanical stimuli, repairs injuries such as concussion, regenerates nerves, and promotes learning and memory. Methods are described in which neural activity is modulated to enhance the acceleration of processing.
[0078] In another embodiment of the present invention, the present invention provides a method for the preparation of bacterial mechanosensitive channels (MscL, MscS , MscK, MscG), plant mechanosensitive channels (MSL2-10), TRPV1-T RPV5 channels, Piezo channels, or their site-specific mutants Heterologously expressed mechanosensitive channels such as It is activated by mechanical stimulation and regulates activity in dormant neurons, resulting in coma and The paper describes a method to achieve recovery from a persistent vegetative state.
[0079] In yet another embodiment of the present invention, the present invention provides a bacterial mechanosensitive channel (MscL, MscL). cS, MscK, MscG), plant mechanosensitive channels (MSL2-10), TRPV1 ~TRPV5 channels, Piezo channels, or their site-specific mutations Heterologously expressed mechanosensitive channels, such as heterologous ones, can be expressed in, for example, blood, cerebrospinal fluid (CSF), The central nervous system (CNS) barrier, such as the blood-brain barrier (BBB), blood-retina barrier, and blood-spinal cord barrier, The NS)-mediated barrier has an osmoregulatory mechanism that is activated by internal or external mechanical stimuli. This document describes how the method is used to
[0080] Another aspect of the present invention is directed to bacterial mechanosensitive channels (MscL, MscS, MscK ... cG), plant mechanosensitive channels (MSL2-10), TRPV1-TRPV5 channels Heterologous, piezochannels, or their site-specific mutants, Mechanosensitive channels expressed in the retina are activated by internal or external mechanical stimuli and mediate the development of Alzheimer's disease. Neurodegenerative diseases, including but not limited to Heimer's disease, Parkinson's disease, and Huntington's disease In chronic diseases, for example, β-amyloid, tau and α-synuclein, and polyglutamine Toxins such as nicotinamide, nicotinamide-binding proteins, and nicotinamide-binding proteins are removed from the central nervous system and penetrate the blood-brain barrier (BBB), blood-retinal barrier, and blood-brain barrier (BLB). The present invention describes a method for using a cerebrospinal fluid as an outlet port to allow fluid to pass through the spinal cord barrier into the bloodstream. do.
[0081] Another aspect of the present invention is directed to bacterial mechanosensitive channels (MscL, MscS, MscK ... cG), plant mechanosensitive channels (MSL2-10), TRPV1-TRPV5 channels , Piezo channels, or their site-specific mutants, Mechanosensitive channels heterologously expressed in mice were activated by internal or external mechanical stimuli. in lung diseases including, but not limited to, coal workers' pneumoconiosis exchange oxygen and carbon dioxide from the alveoli to the capillaries via the pneumocytes and vice versa This document describes how the IEEE 802.11b protocol can be used as a port for
[0082] In yet another embodiment of the present invention, the present invention provides a bacterial mechanosensitive channel (MscL, MscL). cS, MscK, MscG), plant mechanosensitive channels (MSL2-10), TRPV1 ~TRPV5 channels, Piezo channels, or their site-specific mutations Cells expressing mechanosensitive channels, such as heterologous cells, are fused or joined to nanoprobes. The presence or absence of any of these, their duration, frequency and intensity may be adjusted to produce the desired therapeutic result. External mechanical forces that can be adjusted to provide precisely controlled stimulation, molecular transduction, or cell death. or a method is described in which the method is activated by a device providing a magnetic field.
[0083] The present disclosure will now be described more fully hereinafter with reference to the accompanying drawings, in which: Several exemplary embodiments are shown, however the invention may be embodied in many different forms. and should not be construed as being limited to the embodiments set forth herein. These embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art. It is given to you to do so.
[0084] The use of the terms "a" and "an" in the claims and / or specification When used in conjunction with the term "comprising," it means "one" may be used, but the meaning of "one or more," "at least one," "one or more than one" is not Also matches.
[0085] Use of the term "or" in the claims is not expressly permitted. Insofar as "and" is used, it refers only to alternatives or to alternatives that are mutually exclusive. Although used to mean "and / or," the present disclosure refers only to the alternative and / or. Support the definition.
[0086] The terms "a" and "an" are not intended to be used unless the present disclosure expressly requires otherwise. As will be appreciated by those of skill in the art, the term "substantially "Substantially" is defined as most, but not necessarily all, of what is specified ( And includes what is specified. For example, "substantially 90 degrees" includes 90 degrees, and "actually In any disclosed embodiment, "substantially" or " The terms "approximately" and "about" mean "within ~[percent]" of what is stated. Percentages that may be substituted include 0.1%, 1%, 5%, and 10%.
[0087] Throughout this application, the term "about" means that a value is relative to the system used to determine the value. It is used to indicate that the standard deviation of error for a device or method is included.
[0088] Furthermore, a molecule or method that is configured in a particular manner is at least configured in that manner, but It may be configured in other ways than those specifically disclosed.
[0089] "Comprise" (and any form of "comprise", e.g. For example, "comprises" and "comprising" (and any form of have, e.g., "has" and "having"), "include" (and any form of include, e.g. "include s" and "including") and "contain" (and Any form of "ontain", e.g. "contains" and "containing" The term is an open-ended conjunctive verb. As a result, it can be used to link one or more elements, such as "comprises, includes, "comprises", "has", "includes" or "containing A device that "contains" includes one or more elements, but does not necessarily have to have only those elements. Similarly, one or more steps such as "comprises," "has," "," "includes," or "contains" means one or more The method includes, but is not limited to, having only one or more of the steps.
[0090] As used in this specification and claims, "comprising" means (And any form of comprising, e.g. "comprise" and "comp "having" (and any form of having, e.g. For example, "have" and "has" and "including" ), e.g., "includes" and "includ") or "containing "containing" (and any form of "containing", e.g., "containing" The terms "ains" and "contain" are inclusive or open-ended and are used interchangeably. The invention does not exclude additional components or method steps not included in the invention.
[0091] Any of the device, system and method embodiments may be used in conjunction with the steps, components and methods described. Comprise / include / contain Consists of or essentially consists of these, rather than in / have. Therefore, in the scope of the claims, In either case, "consisting of" or "consisting essentially of" are not used. To modify a given claim that would otherwise use an open-ended conjunction, can be used in place of any of the open-ended linking verbs cited above.
[0092] Even if one or more features of an embodiment are not described or shown, Unless expressly prohibited by this disclosure or by the nature of the embodiment, Unless otherwise stated, one or more features of one embodiment may be applied to other embodiments. .
[0093] The specific disclosures of the above references or other documents do not anticipate any general aspect of the present invention. To the extent that the present disclosure may be considered to measure any such prior disclosure, It should be understood that the present invention includes the disclaimer that any of the above-mentioned types are also included. Such disclosures are not anticipated by, and are not obvious from, the disclosures of these publications. However, it is at least one of the unexpected and superior results disclosed or claimed herein. This is due in part to
[0094] The invention disclosed herein below is given by way of illustration only and is therefore not intended to limit the scope of the invention. Further illustrated by way of example, which should not be construed as limiting. EXAMPLES
[0095] Example 1. The experiments outlined below demonstrate that bacterial mechanosensitive channels are involved in the functioning of mammalian cells, particularly ciliary This demonstrates that E. coli MscL (EcMs cL) was selected as the model channel because EcMscL is the most robust. This is because it is a mechanosensitive channel that is highly active and well characterized. The MscL gene from the BL21(DE3) E. coli strain encoding the amino acid monomer was It was codon-optimized for expression in mammalian cells and placed under the control of a TM-specific promoter. Several studies have shown that in the eye, matrix Gla protein (MGP) is expressed in TM cells. It is preferentially expressed and its promoter sequence is used to target gene expression It has been found that M, located at 14886367-14885792 on chromosome 12, The GP promoter sequence (pMGP) was amplified using primers from Linton et al. (2005). The sequence was identified using the GRCh38.p12 gene and aligned against the reverse complement of the human genome. The resulting 576 bp promoter sequence was placed at the 5' end of the EcMscL gene. The fused fluorescent reporters served as visual markers of gene expression and membrane localization. EcMscL is a homo-oligomer and is a post-translationally functional complex. Since fluorescent proteins must be assembled into a single molecule, we strictly select monomeric fluorescent proteins. It was necessary to avoid any interactions that could cause disruption. To achieve this, the monomeric fluorescent protein M-Cherry was fused to the C-terminus of MscL. The DNA segment designed as above was inserted between the two restriction sites BamHI and SalI. The vector was inserted into the GFP-targeting vector [Figure 1A and Figure 1B]. Primary fetal rat trabecular meshwork cells) were transfected with the pMGP-EcMscL-mCherry construct. Both cell types were grown in 35 mm Petri dishes in standard DMEM growth medium 1. 2 pg of pMG was cultured in 10 mL of JetPRIME (PolyPlus). P-EcMscL-mCherry plasmid DNA was delivered to each dish. Fluorescence conjugates of live cells Use confocal microscopy to confirm successful transfection and expression of the fluorescent reporter-linked genes. The samples were excited at 488 nm and a red emission filter was used from 560 to 660 nm. , mCherry fluorescence was visualized. Populations of HEK293 cells [Figure 2A and Figure 2B] and A population of fetal rat trabecular meshwork cells [Figures 3A and 3B] was fluorescent, thereby indicating that Msc L can be expressed in a mammalian host biologically similar to the intended host (human cells). It was shown that.
[0096] Example 2 - The experiments outlined below demonstrate that bacterial mechanosensitive channels are expressed in mammalian cells We demonstrate that these cellulose derivatives retain their original functions and can be used for molecule introduction and osmotic pressure control. EcMscL is a invasive plant that responds to turgor-induced cell membrane expansion. When the EcMscL channel opens, the membrane-impermeable molecule is They can diffuse into and out of cells through pores. When subjected to hypotonic shock in the presence of membrane-impermeable molecules (including dyes or therapeutic agents), Cells expressing EcMscL should take up the molecule. Primary culture of fetal rat trabecular meshwork transfected with scL-mCherry plasmid DNA Cells were incubated with 2 U / mL of Alexa Fluor™ 488 carboxylate succinimide Add 20% v / v water in the presence of diethyl ester (Invitrogen). The cells were then subjected to hypoosmotic shock by excitation at 488 nm and confocal fluorescence imaging. Monitor for 15 min by light microscopy using a green emission filter (505-525 nm). After hypoosmotic shock, red ( Emission filter: 560-660 nm) Only cells expressing fluorescent EcMscL are green The dye was taken up by the cells [Figure 4A-I]. Analysis of the fluorescence images showed that the dye was absorbed by the cells at low After osmotic shock, only cells expressing red fluorescent EcMscL took up the green dye. It has been shown that non-fluorescent cells remain swollen and dark after hypoosmotic shock [Figure 4J]. There was no EcMscL activity (i.e., the extracellular impermeable dye Ale xa No transport of Fluor™ 488 carboxylic acid succinimidyl ester Therefore, red fluorescence correlates with EcMscL activity, and Transfection of the -mCherry construct resulted in functional membrane junctions that provided osmotic adjustment and molecular delivery. We hypothesized that this resulted in the expression of the combined EcMscL-mCherry channel protein. This can be done.
[0097] Example 3 - FIG. 5A shows the effect of M on membrane tension / membrane deformation induced by mechanical force stimulation. The principle of the response of cells sensitized with scL is shown. The principle of pressure control is illustrated in Figure 5B. The experiments outlined below demonstrate the use of bacterial mechanosensitive channels. However, they retain their original functions in mammalian cells and are resistant to external mechanical or osmotic pressure. This demonstrates that EcMsc in mammalian cells can be stimulated by L channel function was confirmed in whole-cell patches of HEK293 and in mice expressing EcMscL-mCherry. This was investigated by recording electrophysiological measurements from TM cells of developing fetal rats. The patch clamp recording setup was performed using an amplifier system (Axon Multiclamp Nikon inverted microscope (700B, Molecular Devices) 130 mM K-gluconate, 7 1 mM KCl, 2 mM NaCl, 1 mM MgCl2, 0.4 mM EGTA, 10 mM M HEPES, 2 mM ATP-Mg, 0.3 mM GTP-Tris, and 20 mM Two stages were used to achieve a resistance of 3-5 MΩ when filled with a solution containing sucrose. Pull micropipettes using a 3D pipette puller (Narshinghe) The micropipette electrode was attached to a micromanipulator. Cl, 10 mM glucose, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl The extracellular solution containing 2 was buffered with 10 mM HEPES (pH 7.3). The photocurrent was measured while the cell was held at approximately 70 mV in the amplifier. The target signal was recorded using patch clamp software (Molecular Devices, Cl A Digidata 1440 (Molecul) interfaced with a The data were digitized using a digital scanner (Clamar Devices). p10 software was used. Patch cells were prepared by adding 20% v / v water. Channel activity was induced by exposing the cells to hypoosmotic shock [Fig. 2C and Fig. 3C A stable gigaohm seal was achieved and current traces were obtained in response to a hypoosmotic shock. Channel activity in HEK293 cells and fetal rat TM cells. Comparison of channel activity in the two cells revealed differences in peak current and open dwell time. [Figure 3D].
[0098] Example 4 - The experiments outlined below demonstrate that EcMscL is expressed in the trabecular meshwork (TM). It has been shown that EcMscL reduces intraocular pressure (IOP), thereby treating glaucoma. This demonstrates that it is possible to deliver a virus to the intraocular pressure (IOP). The study of the effect of scL was carried out in a glucocorticoid-induced mouse model of glaucoma. To induce elevated intraocular pressure (IOP) in wild-type C57BL / 6J mice, 0.1% dexamethasone (DEX) ophthalmic solution was administered to the eyes of the mice three times daily for the duration of the study. The intraocular pressure (IOP) was measured using a TonoVet (rebound tonometer). Intraocular pressure (IOP) measurements were taken three times in each eye and the average measurement was recorded. Mice in the EcMsc group [Figure 6C] showed elevated intraocular pressure (IOP). Adeno-associated virus (AAV) containing the L-mCherry gene was injected into the anterior chamber of the eye (AA V2 / 8-pMGP-EcMscL mCherry was injected intracamerally into the anterior chamber (6.7 5×10 10 The needle was inserted through the cornea anterior to the iridocorneal angle and 3 μl of corneal mucus was injected. The virus was injected into the eye at a rate of 1 μl / min. After injection, the needle was left in place in the eye for 1 minute. After this, the cornea was slowly retracted. Intraocular pressure (IOP) was measured before and weekly after treatment. Compared to the untreated control mice group [see Figure 6C], virus-bearing EcM targeted to the TM We found that intraocular pressure (IOP) decreased 3 weeks after intracameral injection of scL [Fig. 6D, 6E]. At the end of the study, the mice were sacrificed and their eyes were dissected for immunohistochemical analysis. Immunostaining with anti-mCherry antibody confirmed that EcMscL-mCherry is a T The results of this study showed that the expression of TM was normal in M [see Figure 6A and Figure 6B]. Expression of EcMscL in the glaucoma correlates with the reduction of elevated intraocular pressure (IOP) and may be useful for the treatment of glaucoma. We show that it is possible to demonstrate the usefulness of mechanosensitive channels in , bacterial mechanosensitive channels (MscL) or their Heterologously expressed mechanosensitive channels, including site-specific mutants, were generated. Subretinal edema activated by internal or external mechanical stimuli and passive cystoid macular edema , lymphedema, peripheral edema, pulmonary edema, and swelling of the feet, as well as knee and ankle joints associated with osteoarthritis. Provides an alternative route of fluid inflow / outflow in the treatment and prevention of swelling in other joints.
[0099] Example 5 - The experiments outlined below demonstrate the ability of EcMscL(I113L / I70E)-mCh erry (see SEQ ID NO:5) is spatially targeted to organs by non-viral methods. The purpose of this study is to demonstrate that the drug can be delivered to a specific tissue region in vivo. The laser-assisted transfection method used is called nanoenhanced optical delivery (NOD) and uses low-power continuous The wave-wave laser beam is locally induced by surface plasmon resonance near the tissue by gold nanoparticles. This enhances the local temperature rise at the hotspot, causing a temporary increase in the cell membrane. Perforation occurs. Although any tissue can be targeted, the retina was used as an example. First, 1 μl of gold nanorods (GNRs) was injected into the vitreous of a mouse eye. After 45 min, 1 μl of plasmid containing the EcMscL(I113L / I70E) gene was added. The DNA was then injected intravitreally again into the same eye. The retina of the eye was irradiated in a spatially controlled manner using a laser beam. After 3 h, mice were sacrificed, their eyes were fixed, and retinal flat mounts were prepared for immunohistochemistry analysis. Immunostaining with anti-mCherry antibody demonstrated that E cMscL(I113L / I70E)-mCherry expression [Figure 7]. No expression was seen in control eyes.
[0100] Example 6 - The experiments outlined below were carried out using the EcMscL-mCherry gene (SEQ ID NO: 1) was expressed as EcMscL-mCherr carried by adeno-associated virus (AAV). We also demonstrated that the y gene could be expressed in the mouse brain after intravenous injection. The virus was administered through the lateral tail vein. First, the tail was inoculated with a lamp. The vein was then visualized by heating. Approximately 100 μl of virus, a total of approximately 1×10 11 vg (AAV2 / 8-pMGP-EcMscL-mCherry) was injected into the lateral tail vein. Four weeks after injection, mice were sacrificed and their brains were fixed and sectioned for immunohistochemical analysis. Immunostaining with anti-mCherry antibody revealed that EcMscL was expressed in the cerebellar margin [Fig. A, B] and the pons and medulla oblongata regions [Fig. 8C, D]. The results of the study showed that intravenously injected virus crossed the blood-brain barrier and promoted the expression of MscL in the brain. This demonstrates that the present invention can result in transduction of expression.
[0101] Example 7 - The experiments outlined below demonstrate the expression of Mycobacterium tuberculosis MscL (MtMscL) in mammalian cells. It is possible to express and function the above-mentioned enzymes and use them for molecule introduction and osmotic pressure control. This demonstrates that the H37R The MscL gene from M. tuberculosis strain was codon-optimized for expression in mammalian cells; It was N-terminally fused to a signal peptide and C-terminally fused to mCherry (SEQ ID NO:2). Signal peptides are used to target proteins to the plasma membrane and to express fluorescent reporter proteins. These were selected to serve as visual markers of gene expression and membrane localization. HEK293 cells were transfected with the constructs and cultured in standard DMEM-enhanced medium in 35 mm Petri dishes. The cells were cultured in 1 mL of growth medium. A lipofection agent was used to deliver plasmid DNA to the cells. Live cell fluorescence confocal microscopy was used to confirm the successful expression of fluorescent reporter-linked genes. Transfection and expression were confirmed. A red emission filter of 560-660 nm was used to capture mC MtMscL-mCherry fluorescence was visualized. HEK29 transfected with MtMscL-mCherry The population of three cells [Figure 9A] fluoresced, thereby demonstrating that MtMscL is a cellular marker for cellular function in mammalian hosts. In addition, the fluorescence was found primarily in the plasma membrane of the cells, Thereby, successful membrane targeting by the signal peptide was demonstrated.
[0102] MtMscL channel function in mammalian cells was also confirmed by MtMscL-mCherry Electrophysiological measurements were recorded from whole-cell patches of HEK293 cells expressing The patch clamp recording setup was performed using an amplifier system (Axon M The ulticlamp 700B (Molecular Devices) was used. Includes a Nikon inverted fluorescence microscope (TS100) platform. K-gluconate, 7 mM KCl, 2 mM NaCl, 1 mM MgCl2, 0.4 mM 10 mM EGTA, 10 mM HEPES, 2 mM ATP-Mg, 0.3 mM GTP-Tri When filled with a solution containing 20 mM sucrose, the resistance was 3–5 MΩ. To achieve this, a two-stage pipette puller (Narshinghe) was used to pull the micropipettes. The pet was pulled. The micropipette electrode was mounted on a micromanipulator. 150 mM NaCl, 10 mM glucose, 5 mM KCl, 2 mM CaCl2, The extracellular solution containing 1 mM MgCl2 was buffered with 10 mM HEPES (pH 7.3). Current was measured while the cell was held in voltage clamp at approximately 70 mV. The electrophysiological signals were recorded using patch clamp software (Molecular Devices). Digidata 1440 ( The data were digitized using a digital microscope (Molecular Devices, Inc.). The pClamp10 software was used. By adding 20-40% volume / volume water, By exposing patched cells to hypoosmotic shock, channel activity was induced. A stable gigaohm seal was achieved and current traces were obtained after hypoosmotic shock. The MtMscL channel showed channel activity in mammalian cells [Fig. 9B]. It's been proven to work.
[0103] HEK293 cells expressing MtMscL-mCherry were stained with a membrane-impermeable dye, That is, Alexa Fluor™ 488 carboxylic acid succinimidyl ester In the presence of , the cells were subjected to a hypoosmotic shock by adding 20-40% v / v water. The cells were then excited at 543 nm for mCherry and green channel (for membrane-impermeable dyes, 488 nm) and and detection with a 505-525 nm emission filter) for 10-25 minutes. The green and red channels were monitored by confocal fluorescence microscopy [Figure 9C: Analysis of the fluorescence images revealed that after hypoosmotic shock, cells were stained red (mChe rry) Only cells expressing fluorescent MtMscL took up the green-opaque dye. The non-fluorescent cells swelled and remained dark after hypoosmotic shock [Figure 9D]. and no MtMscL activity (i.e., no transport of the impermeable dye out of the cells). Therefore, red fluorescence correlates with MtMscL activity and MtM Transfection with the scL-mCherry construct resulted in functionalization of the osmolarity-adjustable and molecule-delivery-capable cells. This resulted in the expression of membrane-integrated MtMscL-mCherry channel protein. It is possible.
[0104] Example 8 - The experiments outlined below demonstrate the use of a mutant of E. coli MscL (EcMscL), EcM scL(I113L / I70E) can be expressed and function in mammalian cells; It can be used for molecular introduction and osmotic pressure control, and EcMscL (I113 L / I70E) have gating kinetics that differ from the wild-type channel. MscL from the BL21(DE3) Escherichia coli strain encoding the A136 amino acid monomer The gene was codon-optimized for expression in mammalian cells and N-terminally modified with a signal peptide. The fusion was C-terminally fused to mCherry and the I113 and I70 residues were mutated (sequence (See column number 5.) Signal peptides are used to target proteins to the plasma membrane and Optical reporters are selected to serve as visual markers of gene expression and membrane localization; The mutations altered channel kinetics. HEK293 cells were transfected with the constructs and incubated at 35 mm The cells were cultured in 1 mL of standard DMEM growth medium in a Petri dish. Plasmid DNA was delivered into cells using live cell fluorescence confocal microscopy. Successful transfection and expression of the fluorescent reporter-linked gene was confirmed. A red emission filter was used to visualize mCherry fluorescence. The cluster [Figure 10A] emits fluorescence, which allows EcMscL(I113L / I70E) to bind to the mammalian host. It has been shown that it can be expressed in a mammalian host.
[0105] EcMscL (see I113L / I70E) (see SEQ ID NO:5) in mammalian cells Channel function in EcMscL(I113L / I70E)-mCherry expressing cells By recording electrophysiological measurements from whole-cell patches of live HEK293 cells, The patch clamp recording setup was performed using an amplifier system (Axon Multi Niko clamp 700B (Molecular Devices) Includes an inverted fluorescence microscope (TS100) platform manufactured by Nichia. Coniconic acid, 7 mM KCl, 2 mM NaCl, 1 mM MgCl2, 0.4 mM EGT A, 10 mM HEPES, 2 mM ATP-Mg, 0.3 mM GTP-Tris, and Achieve a resistance of 3-5 MΩ when filled with a solution containing 20 mM sucrose To prepare the micropipettes, we used a two-stage pipette puller (Narshinghe). The micropipette electrode was attached to a micromanipulator. 10 mM NaCl, 10 mM glucose, 5 mM KCl, 2 mM CaCl2, 1 mM The extracellular solution containing MgCl2 was buffered with 10 mM HEPES (pH 7.3). Currents were measured while the cells were held in voltage clamp at approximately 70 mV. Physiological signals were recorded using patch clamp software (Molecular Devices, Inc.). Digidata 1440 (Mole) interfaced with Clampex The data were digitized using a PCR microscope (Cyclical Devices). Lamp10 software was used. By adding 20-40% volume / volume water, Channel activity was induced by exposing patched cells to hypoosmotic shock. A consistent gigaohm seal was achieved and current tracing was observed only after the hypoosmotic shock. The EcMscL(I113L / I70E) channel showed potent agonistic activity [Fig. 10B]. It has been demonstrated to be functional in mammalian cells.
[0106] HEK293 expressing EcMscL(I113L / I70E)-mCherry Cells (monitored through a red emission filter (560-660 nm)) were incubated with 100 µL of ... The dye, Alexa Fluor™ 488 carboxylate succinimidyl ester Hypo-osmotic shock by adding 20-40% v / v water in the presence of The cells were then excited at 488 nm and observed for 10–15 min under a confocal fluorescence microscope. The fluorescence images were monitored over a period of time and detected through a green emission filter (505-525 nm). Image analysis revealed that after hypoosmotic shock, red fluorescent EcMscL(I113L / I70E) Only cells expressing the IL-11A receptor were shown to have taken up the green dye (Figure 10C). Fluorescent cells swell and remain dark after hypoosmotic shock, indicating that EcMscL(I113L / I70E) activity (i.e., no transport of the impermeable dye out of the cells). Therefore, red fluorescence indicates EcMscL(I113L / I70E) activity. Correlated with gender, transfection with EcMscL(I113L / I70E)-mCherry construct The membrane-integrated EcMscL (I113L / I7) is capable of osmotic pressure regulation and molecule introduction. 0E)-mCherry channel protein expression. .
[0107] Example 9 - The experiments outlined below demonstrate the expression of Vibrio cholerae MscL (VcMscL) in mammalian cells. ) can be expressed and made functional, and can be used for molecule introduction and osmotic pressure control. This demonstrates that the 0395 cholera The MscL gene from the strain was codon-optimized for expression in mammalian cells and expressed in Signaling. peptide and C-terminally fused to mCherry (see SEQ ID NO:2). A signal peptide is used to target the protein to the plasma membrane and a fluorescent reporter is attached to the They were selected to serve as visual markers of gene expression and membrane localization. K293 cells were transfected with the constructs and cultured in 1 mL of standard DMEM in a 35 mm Petri dish. The cells were cultured in growth medium. Lipofection agents were used to deliver plasmid DNA into the cells. Live cell fluorescence confocal microscopy was used to confirm successful transfection of fluorescent reporter-linked genes. The sample was excited at 543 nm and the red emission spectrum was measured at 560-660 nm. A filter was used to visualize mCherry fluorescence. A] emits fluorescence, thereby demonstrating that VcMscL can be expressed in mammalian hosts. HEK293 cells expressing VcMscL-mCherry (red fluorescent protein) The fluorescence was monitored via a 560-660 nm wavelength filter using Alexa Fluor ( ) 488 In the presence of carboxylic acid succinimidyl ester, 20-40% v / v water The cells were then subjected to a hypoosmotic shock by adding 100 μl of ... The cells were then monitored for 10–25 min by confocal fluorescence microscopy using a green emission filter (50 Fluorescence image analysis revealed that the hypoosmotic shock After the incubation, only cells expressing red fluorescent VcMscL were found to have taken up the green dye. The non-fluorescent cells remain swollen and dark after hypoosmotic shock. and there was no VcMscL activity (i.e., no transport of the impermeable dye out of the cells). Therefore, red fluorescence correlates with VcMscL activity and VcMs Transfection with the cL-mCherry construct resulted in a functional membrane capable of osmotic adjustment and molecule delivery. This resulted in the expression of an integrated VcMscL-mCherry channel protein. It is possible.
[0108] Example 10 - The experiments outlined below used the EcMscL-mCherry gene (SEQ ID NO: This study demonstrates that the IL-11 gene (see No. 1) can be expressed in mouse blood vessels. In control mice, immunostaining with anti-mCherry antibodies revealed no mCherry staining around blood vessels. rry expression was not observed [Figure 12A]. EcMsc at the vascular border of mice transfected with the / I70E (SEQ ID NO: 5) gene L expression [Figure 12B]. Such bacterial mechanosensitive channels expressed in blood vessels The use of internal or external mechanisms to enable delivery of therapeutic agents to target organs and removal of toxins This method allows activation by electrical stimulation. for neurodegenerative diseases, including, but not limited to, Parkinson's disease, and Huntington's disease; In this study, β-amyloid is transported through the blood-brain barrier (BBS), blood-retinal barrier, and blood-spinal cord barrier. By removing α- and tau-synuclein, as well as polyglutamine, from the central nervous system into the bloodstream, This makes it possible.
[0109] Example 11 - The experiments outlined below demonstrate that when expressed in mammalian cells, These results suggest that HEK29 cells generate bursts of electrical activity in a pressure-sensitive environment. 3. Culture the cells in standard DMEM growth medium on multi-electrode array (MEA) Petri dishes. Using a lipofection agent, transfect the EcMscL-mCherry gene (I113L / I 70E, SEQ ID NO:5) plasmid DNA. The extracellular potential of EcMscL-expressing HEK293 cells grown on a petri dish was measured. , measured in the absence and presence of hypoosmotic shock (addition of 20% v / v water), respectively. A burst of spikes was visible in the signal between 13 and 14.5 seconds [Figure 13 ], which shows robust EcMscL channel activity. The results are shown in FIG. 4G. When combined with the results, MscL or its site-specific mutants can When expressed in cells, it acts as an osmoregulatory mechanism in response to osmotic shock and is electrically It has been shown that the serotonin-containing amines can produce serotonin-containing activity, and thus can be used to treat and prevent hypertension and hypotension-related diseases. In the mouse model, hematopoietic stem cells expressing MsCL act as an osmoregulatory mechanism and mediate invasion. Generates red blood cells that are resistant to osmotic shock.
[0110] Example 12 - The experiments outlined below demonstrate E. coli MscL (EcMscL) channel activity , HEK cells (a model of excitable cells such as neurons and cardiac cells) were stimulated with ultrasound. This study demonstrates that HEK293 cells can be induced to undergo cell migration via multi-electrode Culture in standard DMEM growth medium on MEAs Petri dishes and lipofect The cells were transfected with plasmid DNA using a 500-μl ELISA kit. The MEA plates were sonicated. The device was set up to record electrical signals from all electrodes simultaneously. Therefore, any channel activity in the cells attached to the electrode is reflected by the electrical signal from that electrode. The ultrasonic stimulation (pulse width: 250 ms, repetition rate: The cells on the MEA plate were stimulated using ultrasound (frequency: 1.1 MHz, frequency: 2 Hz). Control cells stimulated with EcMscL (not transfected with EcMscL) or with EcMscL No electrical activity was observed in cells that were transfected but not stimulated with ultrasound. [Figure 14A]. Electrical recordings showed spikes in the signal over some electrodes after ultrasound stimulation. The results of the experiment show that MscL channel activity was stimulated by ultrasound [Figure 14B]. Therefore, it is confirmed that bacterial mechanoreceptor channels or their related substances can be detected in nerve cells. Heterologously expressed mechanosensitive channels, such as the site-specific mutants generated by is activated by internal or external mechanical stimuli and regulates activity in dormant neurons. This allows recovery from coma and persistent vegetative state. Heterologously expressed mechanosensitive channels or their generated site-directed mutants Can be activated by internal or external mechanical stimuli and repair injuries such as concussion and modulates neural activity to enhance neural regeneration, learning, and accelerated memory processing. The efficiency of the above external stimulation process can be improved with or without nanoprobe conjugation. However, devices providing external mechanical forces or magnetic fields may be used to control the duration, frequency, and / or duration of stimulation. The frequency and intensity of the radiation can be adjusted to produce the desired therapeutic result. This allows for controlled molecular delivery, stimulation, or cell death.
[0111] Example 13 - The experiments described below demonstrate the expression of mechanosensitive channels (MscL) in corneal epithelial cells. We aimed to determine whether it is possible to express IL-1 in the dry The study was conducted to test whether the drug could be regulated to alleviate diabetic eye disease (DED). Mice were transfected with the EcMscL-mCherry gene (AAV2 / 8-EcMsc L-mCherry, 6.75 × 10 10 Adeno-associated virus containing vg / eye Treatment was by intracameral injection into the anterior chamber of the eye. The needle was inserted through the cornea anterior to the iridocorneal angle and 3 1 μl of virus was injected into the eye at a rate of 1 μl / min. After injection, the needle was placed in the correct position in the eye. After leaving it for 1 min, it was slowly withdrawn. Figure 15 shows the formation of EcMscL-mCherry. Confocal images of sections of transfected mouse corneas. Expression of reporter-mCherry. exhibits red fluorescence detected by excitation at 543 nm and emission at 560-660 nm. Using this viral transduction method, meibomian gland endothelial cells were also found to express MscL. However, these cells can be expressed in a similar manner as in the HEK cell model (Figure 14B). The tear film can be mechanically stimulated (as described above), which enhances the secretion of the aqueous phase of the tear film. , thus providing relief from dry eye disease (DED).
[0112] Example 14 - The following examples provide information on cellular function and therapeutic outcomes associated with that function. To allow for regulation, the MscL-mCherry gene was transfected into the heart and, for example, the kidney. This demonstrates that the gene can be expressed in other vital organs. The EcMscL-mCherry gene carried by the adeno-associated virus (AAV) was The injection was performed via the lateral tail vein. First, a lamp was used to heat the tail, allowing the vein to be visualized. Then, about 100 μl of virus, a total of about 1 × 10 11 vg was injected into the lateral tail vein. Four weeks after injection, the mice were sacrificed and their hearts and kidneys were fixed and subjected to immunohistochemical analysis. Immunostaining with anti-mCherry antibody confirmed the expression of EcMscL in the heart. Figure 16A shows the expression of EcMscL via AAV-based transduction. -Confocal images of mouse kidneys transfected with mCherry. Expression of the reporter mCherry was indicated by characteristic red fluorescence in the emission band. Therefore, mechanosensitive channels (e.g., MscL) or their sites of production Cardiac or renal cells expressing specific mutants can respond to internal or external mechanical stimuli. It is activated by stimulation to reduce osmolarity within the renal system for the treatment and prevention of kidney stones and chronic kidney disease. It can be used as a regulatory or diuretic mechanism.
[0113] Example 15 - The examples described below demonstrate the modulation of cellular function and therapeutic outcomes associated with that function. To enable this, the MscL-mCherry gene can be expressed in the liver. To achieve transduction in the liver, adeno-associated virus (AAV) was used. The EcMscL-mCherry gene carried by the AV was administered through the lateral tail vein. First, a lamp was used to heat the tail to visualize the vein. Then, approximately 100 μl of Viruses, total approximately 1 × 10 11 vg was injected into the lateral tail vein. Four weeks after injection, the mice were sacrificed and their livers fixed and sectioned for immunohistochemistry. Immunostaining with antibodies confirmed the expression of EcMscL-mChe via AAV-based gene transduction. Expression of EcMscL in rry-transfected liver was shown (Figure 16C). Expression of mCherry in the liver was indicated by its characteristic red fluorescence. The bacterial mechanosensitive channel (Ms) expressed in hepatocytes, gallbladder cells, or cholangiocytes of the mouse lineage cL), or their site-specific mutants, The mechanoreceptor channels are activated by internal or external mechanical stimuli for the treatment and prevention of gallstones. It may be used as a bile regulation mechanism to enhance bile secretion.
[0114] Example 16 - The following examples demonstrate the modulation of cellular function and its associated therapeutic outcomes. To achieve this, the MscL-mCherry gene can be expressed in the lung. To achieve transduction in the lungs, the adeno-associated virus (AAV) was used to deliver the The EcMscL-mCherry gene was administered via the lateral tail vein. The tail was heated using a suction pump to visualize the vein. Approximately 100 μl of virus, Total approximately 1×10 11 vg was injected into the lateral tail vein. Four weeks after injection, the mice were sacrificed and The lungs were fixed and sectioned for immunohistochemistry. Staining of cells transfected with EcMscL-mCherry via AAV-based gene transduction Expression of EcMscL in the lungs after injecting the reporter-mChe was shown (Figure 16D). The expression of rry is indicated by red fluorescence. are heterologously expressed in lung cells, including their site-specific mutant forms. The mechanosensitive channels transport oxygen and carbon dioxide from the alveoli to the capillaries and vice versa. These channels / ports on the lung cells can be used as ports to exchange For the treatment of lung diseases, including but not limited to coal workers' pneumoconiosis In addition, it can be further regulated by internal or external mechanical stimuli.
[0115] Table 01: E. coli Ms with signaling peptides for mammalian plasma membrane targeting Amino acid sequence of the synthetic mechanosensitive channel derived from cL. Met Leu Pro Gln Gln Val Gly Phe Val Cys Ala Val Leu Ala Leu Val Cys Cys Ala Ser Gly Met Ser Ile Ile Lys Glu Phe Arg Glu Phe Ala Met Arg Gly Asn Val Val Asp Leu Ala Val Gly Val Ile Ile Gly Ala Ala Phe Gly Lys Ile Val Ser Ser Leu Val Ala Asp Ile Ile Met Pro Pro Leu Gly Leu Leu Ile Gly Gly Ile Asp Phe Lys Gln Phe Ala Val Thr Leu Arg Asp Ala Gln Gly Asp Ile Pro Ala Val Val Met His Tyr Gly Val Phe Ile Gln Asn Val Phe Asp Phe Leu Ile Val Ala Phe Ala Ile Phe Met Ala Ile Lys Leu Ile Asn Lys Leu Asn Arg Lys Lys Glu Glu Pro Ala Ala Ala Pro Ala Pro Thr Lys Glu Glu Val Leu Leu Thr Glu Ile Arg Asp Leu Leu Lys Glu Gln Asn Asn Arg Ser (SEQ ID NO: 1)
[0116] Table 02: Mycobacterium tuberculosis Ms having a signaling peptide for mammalian plasma membrane targeting Amino acid sequence of the synthetic mechanoreceptor channel derived from cL. Met Leu Pro Gln Gln Val Gly Phe Val Cys Ala Val Leu Ala Leu Val Cys Cys Ala Ser Gly Met Leu Lys Gly Phe Lys Glu Phe Leu Ala Arg Gly Asn Ile Val Asp Leu Ala Val Ala Val Val Ile Gly Thr Ala Phe Thr Ala Leu Val Thr Lys Phe Thr Asp Ser Ile Ile Thr Pro Leu Ile Asn Arg Ile Gly Val Asn Ala Gln Ser Asp Val Gly Ile Leu Arg Ile Gly Ile Gly Gly Gly Gln Thr Ile Asp Leu Asn Val Leu Leu Ser Ala Ala Ile Asn Phe Phe Leu Ile Ala Phe Ala Val Tyr Phe Leu Val Val Leu Pro Tyr Asn Thr Leu Arg Lys Lys Gly Glu Val Glu Gln Pro Gly Asp Thr Gln Val Val Leu Leu Thr Glu Ile Arg Asp Leu Leu Ala Gln Thr Asn Gly Asp Ser Pro Gly Arg His Gly Gly Arg Gly Thr Pro Ser Pro Thr Asp Gly Pro Arg Ala Ser Thr Glu Ser Gln (SEQ ID NO: 2)
[0117] Table 03: Vitis aureus with signaling peptides for mammalian plasma membrane targeting Amino acid sequence of the synthetic mechanosensitive channel from Streptococcus aureus MscL. Met Leu Pro Gln Gln Val Gly Phe Val Cys Ala Val Leu Ala Leu Val Cys Cys Ala Ser Gly Met Leu Lys Glu Phe Lys Glu Phe Ala Leu Lys Gly Asn Val Leu Asp Leu Ala Ile Ala Val Val Met Gly Ala Ala Phe Asn Lys Ile Ile Ser Ser Leu Val Glu Asn Ile Ile Met Pro Leu Ile Gly Lys Ile Phe Gly Ser Val Asp Phe Ala Lys Glu Trp Ser Phe Trp Gly Ile Lys Tyr Gly Leu Phe Ile Gln Ser Val Ile Asp Phe Ile Ile Ile Ala Phe Ala Leu Phe Ile Phe Val Lys Ile Ala Asn Thr Leu Met Lys Lys Glu Glu Ala GluGlu Glu Ala Val Val Glu Glu Asn Val Val Leu Leu Thr Glu Ile Arg Asp Leu Leu Arg Glu Lys Lys (SEQ ID NO: 3)
[0118] Table 04: Vibrio cholerae-derived ribosomal proteins with signaling peptides for mammalian plasma membrane targeting Amino acid sequence of a synthetic mechanosensitive channel. Met Leu Pro Gln Gln Val Gly Phe Val Cys Ala Val Leu Ala Leu Val Cys Cys Ala Ser Gly Met Ser Leu Leu Lys Glu Phe Lys Ala Phe Ala Ser Arg Gly Asn Val Ile Asp Met Ala Val Gly Ile Ile Ile Gly Ala Ala Phe Gly Lys Ile Val Ser Ser Phe Val Ala Asp Ile Ile Met Pro Pro Ile Gly Ile Ile Leu Gly Gly Val Asn Phe Ser Asp Leu Ser Phe Val Leu Leu Ala Ala Gln Gly Asp Ala Pro Ala Val Val Ile Ala Tyr Gly Lys Phe Ile Gln Thr Val Val Asp Phe Thr Ile Ile Ala Phe Ala Ile Phe Met Gly Leu Lys Ala Ile Asn Ser Leu Lys Arg Lys Glu Glu Glu Ala Pro Lys Ala Pro Pro Ala Pro Thr Lys Asp Gln Glu Leu Leu Ser Glu Ile Arg Asp Leu Leu Lys Ala Gln Gln Asp Lys (SEQ ID NO: 4)
[0119] Table 05: Mammalian plasma membrane targeting sequences with mutations (I113L / I70E) Amino acid sequence of a synthetic mechanosensitive channel derived from Escherichia coli MscL with a signal transduction peptide Column. Met Leu Pro Gln Gln Val Gly Phe Val Cys Ala Val Leu Ala Leu Val Cys Cys Ala Ser Gly Met Ser Ile Ile Lys Glu Phe Arg Glu Phe Ala Met Arg Gly Asn Val Val Asp Leu Ala Val Gly Val Ile Ile Gly Ala Ala Phe Gly Lys Ile Val Ser Ser Leu Val Ala Asp Ile Ile Met Pro Pro Leu Gly Leu Leu Glu Gly Gly Ile Asp Phe Lys Gln Phe Ala Val Thr Leu Arg Asp Ala Gln Gly Asp Ile Pro Ala Val Val Met His Tyr Gly Val Phe Ile Gln Asn Val Phe Asp Phe Leu Ile Val Ala Phe Ala Leu Phe Met Ala Ile Lys Leu Ile Asn Lys Leu Asn Arg Lys Lys Glu Glu Pro Ala Ala Ala Pro Ala Pro Thr Lys Glu Glu Val Leu Leu Thr Glu Ile Arg Asp Leu Leu Lys Glu Gln Asn Asn Arg Ser (SEQ ID NO: 5)
[0120] Table 06: For mammalian plasma membrane targeting with mutations (I113L / K122T) Amino acids of the synthetic mechanosensitive channel from Escherichia coli MscL bearing a signaling peptide array. Met Leu Pro Gln Gln Val Gly Phe Val Cys Ala Val Leu Ala Leu Val Cys Cys Ala Ser Gly Met Ser Ile Ile Lys Glu Phe Arg Glu Phe Ala Met Arg Gly Asn Val Val Asp Leu Ala Val Gly Val Ile Ile Gly Ala Ala Phe Gly Lys Ile Val Ser Ser Leu Val Ala Asp Ile Ile Met Pro Pro Leu Gly Leu Leu Ile Gly Gly Ile Asp Phe Lys Gln Phe Ala Val Thr Leu Arg Asp Ala Gln Gly Asp Ile Pro Ala Val Val Met His Tyr Gly Val Phe Ile Gln Asn Val Phe Asp Phe Leu Ile Val Ala Phe Ala Leu Phe Met Ala Ile Lys Leu Ile Asn Thr Leu Asn Arg Lys Lys Glu Glu Pro Ala Ala Ala Pro Ala Pro Thr Lys Glu Glu Val Leu Leu Thr Glu Ile Arg Asp Leu Leu Lys Glu Gln Asn Asn Arg Ser (SEQ ID NO: 6)
[0121] The specification and examples provide a complete description of the construction and use of the illustrative embodiments. Specific embodiments may be described with specificity or with reference to one or more individual embodiments. Although the present invention has been described above, those skilled in the art may modify many of the disclosed embodiments without departing from the scope of the invention. Many modifications can be made. Thus, various illustrative embodiments of the device are disclosed herein. It is not intended to be limited to the particular forms shown. Rather, it is intended to provide all embodiments falling within the scope of the claims. Any modifications and alternatives other than those shown are to be construed as equivalent to those of the illustrated embodiment. Some or all of the features may be included. For example, elements may be omitted, or They may be combined into a single structure and / or connections may be replaced. In this case, further studies with comparable or different properties and addressing the same or different problems may be conducted. To produce an embodiment, aspects of any embodiment described above may be combined with any other embodiment described. Similarly, the advantages and benefits described above may be combined in any one embodiment. It is understood that the present invention may relate to the embodiment or to several embodiments. It will be.
[0122] While the compositions and methods of the present invention have been described in terms of preferred embodiments, Without departing from the concept, spirit and scope of the compositions and / or methods described herein. It will be appreciated by those skilled in the art that variations may be applied to the method steps or to the order of the method steps. More specifically, to the extent that the same or similar results are achieved, Certain agents which are both chemically and physiologically related may be substituted for the agents described herein. It will be apparent that such similar substitutes and modifications as are apparent to those skilled in the art are also included herein. are deemed to be within the spirit, scope and concept of the present invention.
[0123] Moreover, the claims may be amended to use the phrases "means for" or "step for" to refer to the same Each of these terms is intended to be construed as construed as meaningless unless such a limitation is expressly recited in a given claim. It is not intended to include the limitations of plus function or step plus function. The provisions of this section do not include, and should not be construed as including, item It is understood that the following items form part of the disclosure of the invention as defined herein: More specifically, the invention herein relates to a combination of features as detailed below. The term may be defined by any combination of features of the claims of this application. It may be used to correct. 1. When expressed on mammalian cell membranes, they sense pressure changes and respond to intracellular pressure or aqueous fluids. and MscL1 protein, which regulates the transport of molecules, including but not limited to therapeutic molecules. The L1 protein has SEQ ID NO: 1, and the MscL1 protein and its generated site Specific mutant synthetic polypeptide sequences. 2. One or more mutations, or combinations of mutations, affect pressure sensitivity, pore size, gating, or modulates the dynamics of the gene, and mutations and / or deletions The amino acid residue corresponding to amino acid I at position 113 of the MscL sequence (SEQ ID NO:1) I to L substitution in the group leads to ultrasonically activated sonic response at very low pressures and The pore size of the MscL channel can be adjusted to control the size of molecules that can be transported through the channel. Regulating, an amino acid corresponding to amino acid A at position 131 of MscL (SEQ ID NO: 1) Substitution of A with H or C in a residue, Adjusting the size of the MscL nanovalve and controlling diffusion and active transport through the nanovalve The amino acid residue corresponding to amino acid A at position 133 of MscL (SEQ ID NO: 1) controls substitution of A with H or C in the group; At the amino acid residue corresponding to the amino acid G at position 43 of MscL (SEQ ID NO: 1), Substitution of G with any of the other 19 naturally occurring amino acids results in a low-threshold activating elongation domain. Providing increased sensitivity to tension and pressure; To control MscL channel kinetics and mechanosensitivity, MscL (SEQ ID NO: 1) At an amino acid residue corresponding to amino acid I at position 70, with naturally occurring amino acids, Amino acid sequence at position 44 of MscL (SEQ ID NO: 1) enhances pressure sensitivity and shortens release time an amino acid substitution of V to C at the amino acid residue corresponding to the acid V; MscL to increase pressure sensitivity, decrease mean open time, and lower transition barrier (SEQ ID NO: 1), Amino acid substitution to D or E, MscL to increase pressure sensitivity, decrease mean open time, and lower transition barrier Q to Q at the amino acid residue corresponding to the amino acid Q at position 77 of (SEQ ID NO: 1) Amino acid substitutions to C, P, F, W, Y, or H; of MscL (SEQ ID NO: 1) to enhance sensitivity to higher gating thresholds. an amino acid substitution of L to C at the amino acid residue corresponding to amino acid L at position 40; Positions in MscL (SEQ ID NO: 1) that modulate the mechanosensitivity and kinetics of the MscL channel At the amino acid residue corresponding to the amino acid K at position 122, any negatively charged Substitution of an amino acid with Amino acids at positions 39 or 42 of MscL (SEQ ID NO: 1) for functional alteration A substitution of D with any amino acid at the amino acid residue corresponding to the acid D of said pressure sensor. Position(s) 13 of MscL (SEQ ID NO: 1) for increased sensitivity and reduced open time a deletion of amino acid(s) from 1 to 133, 131 to 136, or 131 to 157; Selected from, but not limited to, Item 1. The protein according to item 1. 3. When expressed on mammalian cell membranes, they sense pressure changes and respond to intracellular pressure or aqueous fluids. and MscL2 protein, which regulates the transport of molecules, including but not limited to therapeutic molecules. The L2 protein has SEQ ID NO:2, and the MscL2 protein and its generated site Specific mutant synthetic polypeptide sequences. 4. When expressed on mammalian cell membranes, they sense pressure changes and react to intracellular pressure or aqueous fluids. and MscL3 protein, which regulates the transport of molecules, including but not limited to therapeutic molecules. The L3 protein has SEQ ID NO: 3, and the MscL3 protein and its generated site Specific mutant synthetic polypeptide sequences. 5. When expressed on mammalian cell membranes, they sense pressure changes and react to intracellular pressure or aqueous fluids. and MscL4 protein, which regulates the transport of molecules, including but not limited to therapeutic molecules. The L4 protein has SEQ ID NO: 4, and the MscL4 protein and its generated site Specific mutant synthetic polypeptide sequences. 6. One or more MscL proteins, or different MscL proteins, expressed in a cell A chimera of sequence elements of the polypeptide or MscL monomers concatamer is provided as a signal peptide. from the N-terminal Golgi export signal, the endoplasmic reticulum (ER) transport signal, the membrane transport signal, and the N-terminal and in particular, The signal consists of MLPQQVGFVCAVLALVCCASG, Optionally, the signal sequence is MGRLLALVVGAALVSSAC, MAVPA RTCGASRPGPART, or any signaling peptide sequence; 6. The synthetic polypeptide sequence according to any one of items 1 to 5. 7. Bacterial machinery optionally comprising MscL, MscS, MscK, or MscG Receptor channels, plant mechanosensitive channels (MSL2-10), TRPV1-TRPV5 channels Optionally, a specific mutant of a channel, a piezo channel, or a site where the channel or piezo channel is generated is selected. The heterologously expressed mechanosensitive channels, which contain Tension occurs in cells, including trabecular meshwork cells, epithelial cells, and other cells of the body, that are subjected to osmotic pressure. For use in a method as a force-activated pressure relief valve, A protein described in any one of items 1 to 6. 8. MscL homologue strains are effective against Escherichia coli, Mycobacterium tuberculosis, Vibrio cholerae, Bacillus subtilis, Mycobacterium leprae, and green sulfur light Synthetic bacteria, Thermus thermophilus, Haemophilus influenzae, Erwinia carotovora, Pseudomonas fluorescens, Clostridium ruciferum, Staphylococcus aureus, Enterococcus faecalis, Lactobacillus lactis, Melanocortis, Caulobacter - crescentus, Histolyticum, Fusobacterium nucleatum subsp., Lotus japonicus, Hemorrhagic septicemia soft rot bacteria, Pseudomonas aeruginosa, Salmonella typhimurium, Salmonella enterica, Pierce's disease bacteria, Corynebacterium M. glutamicum, Deinococcus radiodurans, Lactococcus lactis, Ralstonia solanacearum, Rhizobium rufalfa, Streptococcus pneumoniae, Streptococcus pyogenes, Streptomyces coelicolor, Methanosarcina acetivorans, Listeria innocua, Listeria monocytogenes The protein of item 7, including, but not limited to, MscL from Ness. 9. Mechanosensitive channels (e.g., MscL) are expressed via viral or non-viral vectors The channel is delivered by the matrix Gla protein (MGP) promoter. By using a promoter that optionally includes, but is not limited to, a selected fiber Transgenic pressure regulator in glaucomatous eye damaged cells in trabecular meshwork (TM) cells 8. The protein according to item 7, which acts as a protein. 10. The viral vector is an adenovirus, an adeno-associated virus, or a lentivirus. and a mechanosensitive channel promoter for target site(s), selected from, but not limited to, Non-viral methods for delivery of transgenes include the use of light, laser, ultrasound, or electric fields. Physical methods, optionally including lipid carriers, or DEAA-dextran, The protein according to item 9, optionally including, but not limited to, chemical methods. quality. 11. Mechanosensitive channels function as alternative outflow actuators and are involved in the regulation of TM function. Natural paracytosis and transcytosis in the movement of aqueous humor through epithelial cells and thereby reducing outflow resistance for the treatment of primary open angle glaucoma (POAG). 8. The protein according to item 7, which reduces intraocular pressure (IOP). 12. Mechanosensitive channels, their variants, and site-specific mutants generated For example, intraocular pressure greater than 20 mmHg, or between 120 and 200 mmHg (systolic) and 8 Intra-arterial pressure between 0 and 110 mmHg (diastolic) or intracranial pressure greater than 15 mmHg, Item 7, which is activated by selected, but not limited to, physiological and non-physiological pressures. The protein according to claim 1. 13. Mechanosensitive channels, their variants, and site-specific mutants generated Activation at the target site with the assistance of an external device, optionally including ultrasonic actuation or other physical perturbation. 8. The protein according to item 7, which is activated. 14. The expression of mechanosensitive channels in corneal epithelial cells is altered with or without mechanical stimulation. Regardless of the cause, it enhances the secretion of the aqueous phase of the tear film and relieves dry eye disease (DED). 7. The protein according to claim 7. 15. Bacterial machinery optionally comprising MscL, MscS, MscK, or MscG Mechanosensitive channels, plant mechanosensitive channels (MSL2-10), TRPV1-TRPV5 The channel, piezo channel, or a mutant specific to the site where the channel or piezo channel was generated is selected. Heterologously expressed mechanosensitive channels selectively containing In the arterial system, the osmoregulatory mechanism is activated by internal or external mechanical stimuli. 8. The protein according to item 7, for use in epithelial cells of. 16. Bacterial machinery optionally comprising MscL, MscS, MscK, or MscG Mechanosensitive channels, plant mechanosensitive channels (MSL2-10), TRPV1-TRPV5 The channel, piezo channel, or a mutant specific to the site where the channel or piezo channel was generated is selected. A mechanosensitive channel selectively containing the endothelial cell is involved in hypertension and hypotension when expressed in hematopoietic stem cells. It acts as an osmoregulatory mechanism and provides resistance to osmotic shock in the treatment and prevention of related diseases. 8. The protein according to item 7, which produces red blood cells having the desired properties. 17. Bacterial machinery optionally comprising MscL, MscS, MscK, or MscG Mechanosensitive channels, plant mechanosensitive channels (MSL2-10), TRPV1-TRPV5 The channel, piezo channel, or a mutant specific to the site where the channel or piezo channel was generated is selected. Heterologously expressed mechanosensitive channels selectively containing acetylcholine have been shown to be useful in the treatment of kidney stones and chronic kidney disease. In the prevention and treatment of osteoporosis, osmoregulatory mechanisms or benefits activated by internal or external mechanical stimuli 8. The protein according to item 7, for use in the renal system as a urinary mechanism. 18. Bacterial machinery optionally comprising MscL, MscS, MscK, or MscG Mechanosensitive channels, plant mechanosensitive channels (MSL2-10), TRPV1-TRPV5 The channel, piezo channel, or a mutant specific to the site where the channel or piezo channel was generated is selected. Heterologously expressed mechanosensitive channels selectively containing endothelial cells have potential applications in the treatment and prevention of gallstones. The hepatic system includes the liver, gallbladder, and ventricles as bile regulating mechanisms that are activated by internal or external mechanical stimuli. Or the protein according to item 7, for use in bile duct cells. 19. Bacterial machinery optionally comprising MscL, MscS, MscK, or MscG Mechanosensitive channels, plant mechanosensitive channels (MSL2-10), TRPV1-TRPV5 The channel, piezo channel, or a mutant specific to the site where the channel or piezo channel was generated is selected. Heterologously expressed mechanosensitive channels selectively containing endothelial cells have potential applications in the treatment and prevention of edema. As an osmoregulatory mechanism activated by internal or external mechanical stimuli, and for fluid as an alternative outflow / inflow pathway, said edema optionally being passive subretinal edema; Associated with cystoid macular edema, lymphedema, peripheral edema, pulmonary edema, and foot edema, and osteoarthritis 7. The protein according to claim 7, including, but not limited to, swelling of the knee joint and other joints Quality. 20. Bacterial machinery optionally comprising MscL, MscS, MscK, or MscG Mechanosensitive channels, plant mechanosensitive channels (MSL2-10), TRPV1-TRPV5 The channel, piezo channel, or a mutant specific to the site where the channel or piezo channel was generated is selected. Heterologously expressed mechanosensitive channels selectively containing β-amyloides are useful in treating erectile dysfunction in the reproductive system. For use internally or in the treatment and prevention of ovarian hyperplasia, vaginal dryness, benign prostatic hyperplasia, and polycystic ovarian syndrome. as an osmoregulatory mechanism activated by external mechanical stimuli and as a substitute for fluid 8. The protein according to item 7, which is used as an effective efflux / influx pathway. 21. Bacterial machinery optionally comprising MscL, MscS, MscK, or MscG Mechanosensitive channels, plant mechanosensitive channels (MSL2-10), TRPV1-TRPV5 The channel, piezo channel, or a mutant specific to the site where the channel or piezo channel was generated is selected. The heterologously expressed mechanosensitive channels selectively contain endothelial cells that are activated by internal or external mechanical stimuli. as an osmoregulatory mechanism activated by the skin, and optionally including dysfunction of sweat glands. 2. The method of claim 1, further comprising: providing a skin-related treatment for a skin disorder comprising administering to said skin a therapeutic agent to said skin; 7. The protein according to claim 7. 22. Bacterial machinery optionally comprising MscL, MscS, MscK, or MscG Mechanosensitive channels, plant mechanosensitive channels (MSL2-10), TRPV1-TRPV5 The channel, piezo channel, or a mutant specific to the site where the channel or piezo channel was generated is selected. Heterologously expressed mechanosensitive channels selectively containing β-amyloides in the treatment of idiopathic intracranial hypertension as a polymeric pressure relief valve activated by an internal or external mechanical stimulus, and as a 8. The protein according to item 7, which is used as an alternative efflux pathway for the body. 23. Bacterial machinery optionally comprising MscL, MscS, MscK, or MscG Mechanosensitive channels, plant mechanosensitive channels (MSL2-10), TRPV1-TRPV5 The channel, piezo channel, or a mutant specific to the site where the channel or piezo channel was generated is selected. Heterologously expressed mechanosensitive channels selectively containing the endothelial cells may be useful in the treatment of diseases involving the eye. Activated by internal or external mechanical stimulation for enhanced drug delivery to enhance efficacy 8. The protein according to item 7, which is used as an intracellular transmembrane port for translocation. 24. Specific receptors, optionally including epidermal growth factor receptor (EGFR), or pH environment Using the expression of mechanosensitive channels in cancer cells targeted by Bioengineer free "leaky" channels or overstimulate the channels 8. The protein according to Item 7, which promotes cell death by inhibiting the activation of the cytoplasmic receptor. 25. Bacterial machinery optionally comprising MscL, MscS, MscK, or MscG Mechanosensitive channels, plant mechanosensitive channels (MSL2-10), TRPV1-TRPV5 The channel, piezo channel, or a mutant specific to the site where the channel or piezo channel was generated is selected. Heterologously expressed mechanoreceptor channels, which selectively contain mechanoreceptor channels, are useful in treating, for example, pain, epilepsy, stroke, and optionally including, but not limited to, cardiovascular diseases and neurological diseases such as muscular dystrophies. For the treatment and prevention of diseases that cannot be treated with conventional methods, such as the use of human endothelial cells, including neuronal cells, cardiac cells, and muscle cells, 8. The protein according to item 7, for use in stimulating a cell. 26. Bacterial machinery optionally comprising MscL, MscS, MscK, or MscG Mechanosensitive channels, plant mechanosensitive channels (MSL2-10), TRPV1-TRPV5 The channel, piezo channel, or a mutant specific to the site where the channel or piezo channel was generated is selected. The heterologously expressed mechanoreceptor channels selectively contain internal or external receptors in neurons. and modulates neural activity by mechanical stimulation of the Repair and regulate neural activity to enhance neural regeneration, learning, and accelerate memory processing 8. The protein according to Item 7, 27. Bacterial machinery optionally comprising MscL, MscS, MscK, or MscG Mechanosensitive channels, plant mechanosensitive channels (MSL2-10), TRPV1-TRPV5 The channel, piezo channel, or a mutant specific to the site where the channel or piezo channel was generated is selected. The heterologously expressed mechanoreceptor channels selectively contain internal or external receptors in neurons. It is activated by mechanical stimulation of the brain and regulates activity in dormant neurons, resulting in coma and 8. The protein according to item 7, which realizes recovery from a persistent vegetative state. 28. Bacterial machinery optionally comprising MscL, MscS, MscK, or MscG Mechanosensitive channels, plant mechanosensitive channels (MSL2-10), TRPV1-TRPV5 The channel, piezo channel, or a mutant specific to the site where the channel or piezo channel was generated is selected. The heterologously expressed mechanosensitive channels selectively contain Central nervous system (CNS) mediators, such as the fluid-brain barrier (BBB), blood-retina barrier, and blood-spinal cord barrier In the barrier, it serves as an osmoregulatory mechanism that is activated by internal or external mechanical stimuli. 8. The protein according to Item 7, which is used in 29. Bacterial machinery optionally comprising MscL, MscS, MscK, or MscG Mechanosensitive channels, plant mechanosensitive channels (MSL2-10), TRPV1-TRPV5 The channel, piezo channel, or a mutant specific to the site where the channel or piezo channel was generated is selected. The heterologously expressed mechanosensitive channels selectively bind to the endothelial cells in response to internal or external mechanical stimuli. Activated and optionally including Alzheimer's disease, Parkinson's disease, and Huntington's disease In neurodegenerative diseases, including but not limited to, beta amyloid, tau and alpha synuclein Removes toxins such as rhein and polyglutamine from the central nervous system and prevents them from crossing the blood-brain barrier ( BBB), the blood-retinal barrier, and the blood-spinal cord barrier into the bloodstream. 8. The protein according to Item 7, which is used as a 30. Bacterial machinery optionally comprising MscL, MscS, MscK, or MscG Mechanosensitive channels, plant mechanosensitive channels (MSL2-10), TRPV1-TRPV5 The channel, piezo channel, or a mutant specific to the site where the channel or piezo channel was generated is selected. The mechanosensitive channels heterologously expressed in pulmonary cells selectively react with internal or external mechanisms. These include, but are not limited to, coal pneumoconiosis (coal workers' pneumoconiosis), which is activated by physical stimuli. In lung diseases, not limited to those involving the lungs, the blood is transported from the alveoli to the capillaries via the lung cells, or vice versa. 8. The protein according to claim 7, which is used as a port for exchanging oxygen and carbon dioxide. quality. 31. Bacterial machinery optionally comprising MscL, MscS, MscK, or MscG Mechanosensitive channels, plant mechanosensitive channels (MSL2-10), TRPV1-TRPV5 The channel, piezo channel, or a mutant specific to the site where the channel or piezo channel was generated is selected. Optionally, the cell expressing the mechanosensitive channel may be fused to a nanoprobe or With or without bonding, activated by a device that provides an external mechanical force or a magnetic field; The duration, frequency, and strength of the external mechanical or magnetic field are adjusted to produce the desired therapeutic result. Item 7, which is tunable for controlled stimulation, molecular introduction, or cell death. of protein.
Claims
1. A large conductance mechanosensitive channel (MscL1) protein or an MscL1 protein comprising the generation of a site-directed mutation therein, the MscL1 protein or the MscL1 protein comprising a mutation therein comprises at least 95% sequence identity to SEQ ID NO:1; The MscL1 protein or an MscL1 protein containing a mutation therein senses pressure changes when expressed on a mammalian cell membrane and regulates intracellular pressure or the transport of aqueous fluids and molecules including therapeutic molecules, the MscL1 protein or an MscL1 protein containing the generation of site-specific mutations therein.
2. The MscL1 protein of claim 1 or an MscL1 protein comprising site-specific mutations therein, wherein the mutant is selected from one or more substitutions, deletions or combinations thereof, and the one or more substitutions, deletions or combinations thereof have a function of regulating pressure sensitivity, pore size, gate opening or closing, or kinetics.
3. 2. The MscL1 protein according to claim 1, wherein the MscL1 protein comprising MscL1 or a mutation thereof is a single protein, a concatemer of the MscL1 protein or a mutant thereof.
4. The MscL1 protein of claim 2 or an MscL1 protein comprising a site-specific mutation therein, wherein at least one substitution is an I to L substitution at an amino acid residue corresponding to amino acid I at position 113 of SEQ ID NO:1, and at least one substitution is an I to E substitution at an amino acid residue corresponding to amino acid I at position 70 of SEQ ID NO:
1.
5. Use of the MscL1 protein of claim 1 or the MscL1 protein including the generation of site-specific mutants therein, including heterologously expressed mechanosensitive channels, mutants thereof and generated site-specific mutants thereof; bacterial mechanosensitive channels; MscL homologue strains; plant mechanosensitive channels (MSL2-10); TRPV1-TRPV5 channels; and Piezo channels, or generated site-specific mutants thereof from alternative strains, in the manufacture of a medicament for the treatment of tension-activated pressure relief valves in cells, including trabecular meshwork cells, epithelial cells, and other cells of the body, subjected to mechanical or osmotic pressure.
6. The MscL homologue strain is selected from the group consisting of Escherichia coli, Mycobacterium tuberculosis, Vibrio cholerae, Bacillus subtilis, Mycobacterium leprae, green sulfur photosynthetic bacteria, Thermus thermophilus, Haemophilus influenzae, Erwinia carotovora, Pseudomonas fluorescens, Clostridium perfringens, Staphylococcus aureus, Enterococcus faecalis, Lactobacillus lactis, Malta fever, Caulobacter crescentus, Clostridium histolyticum, Fusobacterium nucleatum subsp., Lotus japonicus, Borrelia hemorrhagica, Salmonella typhimurium, Salmonella enterica serovar Typhimurium, Borrelia typhi, Corynebacterium burgdorferi, and Corynebacterium truncatula.
6. Use of the MscL1 protein of claim 5, comprising at least one selected from the group consisting of Bacillus subtilis, Bacillus solanacearum, Bacillus subtilis, Bacillus oxysporum, Bacillus subtilis, Bacillus spp., Bacillus rhizobialis, Bacillus subtilis, Bacillus subtilis, Bacillus subtilis, Bacillus oxysporum, Bacillus subtilis ...
7. The use of MscL1 protein as described in claim 5, or MscL1 protein including the generation of site-specific mutations therein, wherein the mechanosensitive channel is delivered by a viral vector or a non-viral method, and the channel acts as a transgenic pressure regulatory mechanism in trabecular meshwork cells, in damaged cells of the glaucoma eye, by using a promoter optionally including the matrix Gla protein (MGP) promoter.
8. The use of MscL1 protein or MscL1 protein comprising the generation of site-specific mutations therein as described in claim 7, wherein the viral vector is at least one selected from adenovirus, adeno-associated virus, and lentivirus, and the non-viral method for delivery of mechanosensitive channel-promoting genes to the target site(s) is selected from physical methods optionally including light, laser, ultrasound, or electric field, or chemical methods optionally including lipid carriers, or DEAA-dextran.
9. Use of the MscL1 protein described in claim 5 or an MscL1 protein including the generation of site-specific mutations therein in the manufacture of a medicament for the treatment of primary open-angle glaucoma (POAG) to reduce outflow resistance and lower intraocular pressure (IOP), wherein the mechanosensitive channel functions as an alternative outflow actuator and assists natural paracytosis and transcytosis in the movement of aqueous humor through endothelial cells of the trabecular meshwork.
10. The use of the MscL1 protein or the MscL1 protein comprising the generation of site-specific mutations therein as described in claim 5, wherein the mechanosensitive channel, its mutants, and its generated site-specific mutants are activated at at least one of physiological and non-physiological pressures selected from at least one of intraocular pressures greater than 20 mmHg, or intraarterial systolic pressures of 120-200 mmHg and intraarterial diastolic pressures of 80-110 mmHg, or intracranial pressures greater than 15 mmHg.
11. The use of the MscL1 protein as described in claim 5 or the MscL1 protein including the generation of site-specific mutations therein, wherein the mechanosensitive channel, its variants, and its generated site-specific mutants are activated at the target site with the assistance of an external device, optionally including ultrasonic actuation or other physical perturbation.
12. Use of the MscL1 protein described in claim 5 or an MscL1 protein containing the generation of a site-specific mutation therein in the manufacture of a medicament for the treatment of alleviating dry eye disease (DED) by enhancing the secretion of the aqueous phase of the tear film in corneal epithelial cells, whether or not accompanied by mechanical stimulation, in which expression of the mechanosensitive channel, its mutants, and its mutants specific to the site where it is generated, is accompanied by mechanical stimulation or not.
13. 6. Use of the MscL1 protein according to claim 5 or the MscL1 protein comprising the generation of site-specific mutations therein, wherein heterologously expressed mechanosensitive channels, optionally comprising bacterial mechanosensitive channels, plant mechanosensitive channels (MSL2-10), TRPV1-TRPV5 channels, Piezochannels, or their generated site-specific mutants, for use as osmoregulatory agents, are activated in epithelial cells of the arterial system by internal or external mechanical stimulation in the manufacture of a medicament for the treatment and prevention of hypotension and hypertension.
14. 6. Use of the MscL1 protein of claim 5 or an MscL1 protein comprising the generation of site-specific mutations therein, in the manufacture of a medicament for the treatment and prevention of hypertension and hypotension related diseases, wherein the mechanosensitive channels, variants thereof, and variants thereof, optionally comprising bacterial mechanosensitive channels, plant mechanosensitive channels (MSL2-10), TRPV1-TRPV5 channels, Piezo channels, or their generated site-specific mutants, when expressed in hematopoietic stem cells, act as osmoregulators and generate red blood cells resistant to osmotic shock.
15. 6. Use of the MscL1 protein according to claim 5 or the MscL1 protein comprising the generation of site-specific mutations therein, wherein heterologously expressed mechanosensitive channels, optionally comprising bacterial mechanosensitive channels, plant mechanosensitive channels (MSL2-10), TRPV1-TRPV5 channels, Piezochannels or their generated site-specific mutants, for use as osmoregulators or diuretics, variants thereof and their generated site-specific mutants are activated by internal or external mechanical stimuli within the renal system in the manufacture of a medicament for the treatment and prevention of kidney stones and chronic kidney disease.
16. 6. Use of the MscL1 protein according to claim 5 or the MscL1 protein comprising the generation of site-specific mutations therein, wherein heterologously expressed mechanosensitive channels, variants thereof and the generated site-specific mutants thereof for use as bile regulators, optionally comprising bacterial mechanosensitive channels, plant mechanosensitive channels (MSL2-10), TRPV1-TRPV5 channels, Piezochannels or generated site-specific mutants thereof, are activated by internal or external mechanical stimuli in liver, gallbladder or bile duct cells of the hepatic system in the manufacture of a medicament for the treatment and prevention of gallstones.
17. 6. Use of the MscL1 protein according to claim 5 or the MscL1 protein comprising the generation of site-specific mutations therein, wherein heterologously expressed mechanosensitive channels, variants thereof and their generated site-specific mutants, for use as osmoregulatory agents, optionally comprising bacterial mechanosensitive channels, plant mechanosensitive channels (MSL2-10), TRPV1-TRPV5 channels, Piezochannels or generated site-specific mutants thereof, are activated by internal or external mechanical stimuli and alternative outflow / inflow pathways for fluids, in the manufacture of a medicament for the treatment and prevention of edema, optionally comprising passive subretinal edema, cystoid macular edema, lymphedema, peripheral edema, pulmonary edema, and edema of the feet, and knee joints associated with osteoarthritis.
18. 6. Use of the MscL1 protein according to claim 5 or the MscL1 protein comprising the generation of site-specific mutations therein, wherein heterologously expressed mechanosensitive channels, optionally comprising bacterial mechanosensitive channels, plant mechanosensitive channels (MSL2-10), TRPV1-TRPV5 channels, Piezochannels, or their generated site-specific mutants, for use as alternative inflow / outflow pathways for osmoregulators and fluids, variants thereof, and their generated site-specific mutants are activated by internal or external mechanical stimuli in the manufacture of a medicament for the treatment and prevention of erectile dysfunction, vaginal dryness, benign prostatic hyperplasia, and polycystic ovary syndrome in the reproductive system.
19. Heterologously expressed, optionally including bacterial mechanosensitive channels, plant mechanosensitive channels (MSL2-10), TRPV1-TRPV5 channels, Piezo channels, or site-specific mutants thereof; Mechanosensitive channels for use as osmoregulators, variants thereof and their generated site-specific mutants are activated by internal or external mechanical stimuli and alternative inflow / outflow pathways for fluids in the manufacture of a medicament for the treatment of any skin-related disease, optionally including sweat gland dysfunction; Mechanosensitive channels for use as polymeric pressure relief valves, variants thereof, and their generated site-specific mutants activated by internal or external mechanical stimuli and alternative outflow pathways for fluids in the treatment of idiopathic intracranial hypertension; Mechanosensitive channels for use as intracellular transmembrane ports, variants thereof, and generated site-specific mutants thereof, activated by internal or external mechanical stimuli for enhanced drug delivery to increase the efficacy of treatments for diseases including cancer; Mechanosensitive channels, variants thereof, and site-specific mutants thereof for use as stimuli for cells, including neuronal, cardiac, and muscle cells, for the treatment and prevention of diseases, optionally including neurological diseases; 6. The MscL1 protein of claim 5, which is:
20. Use of the MscL1 protein of claim 5 or an MscL1 protein comprising the generation of site-specific mutations therein in the manufacture of a medicament for treatment to promote cell death by bioengineering a constitutively open "leaky" channel or overstimulating the channel, wherein the expression of the mechanosensitive channel, its mutants, and its mutants specific to the site where it was generated in cancer cells is targeted by a specific receptor, optionally including the epidermal growth factor receptor (EGFR), or by the pH environment.
21. Heterologously expressed mechanosensitive channels, variants thereof, and variants thereof, optionally including bacterial mechanosensitive channels, plant mechanosensitive channels (MSL2-10), TRPV1-TRPV5 channels, Piezochannels, or their derived site-specific mutants, are activated in neuronal cells by internal or external mechanical stimuli to: For use in the manufacture of a medicament for the treatment of modulating neural activity to optionally repair injuries, including concussion, and enhance neural regeneration, learning and accelerated memory processes; or Used to modulate activity in dormant neurons to effect recovery from coma and persistent vegetative state, 6. Use of the MscL1 protein according to claim 5 or the MscL1 protein comprising the generation of site-specific mutations therein.
22. 6. Use of the MscL1 protein according to claim 5 or the MscL1 protein comprising the generation of site-specific mutations therein, for the manufacture of a medicament for the treatment of heterologously expressed mechanosensitive channels, variants thereof and variants thereof, optionally comprising bacterial mechanosensitive channels, plant mechanosensitive channels (MSL2-10), TRPV1-TRPV5 channels, Piezochannels or their generated site-specific mutants, which are activated by internal or external mechanical stimuli and serve as an outflow outlet allowing the removal of toxins from the central nervous system.
23. 6. Use of the MscL1 protein of claim 5 or an MscL1 protein comprising the generation of site-specific mutations therein for use in the manufacture of a medicament for the treatment of mechanosensitive channels, variants thereof and variants thereof, optionally comprising bacterial mechanosensitive channels, plant mechanosensitive channels (MSL2-10), TRPV1-TRPV5 channels, Piezo channels or their generated site-specific mutants, heterologously expressed in lung cells, as a port for the exchange of oxygen and carbon dioxide from the alveoli to the capillaries or vice versa via lung cells in lung diseases, optionally including but not limited to coal pneumoconiosis (coal workers' pneumoconiosis), where the mechanosensitive channels, variants thereof and variants thereof and their generated site-specific mutants are activated by internal or external mechanical stimuli.
24. 6. Use of MscL1 protein or MscL1 protein comprising the generation of site-specific mutations therein according to claim 5, wherein cells expressing mechanosensitive channels, variants thereof and variants thereof specific to their generated site, optionally including bacterial mechanosensitive channels, plant mechanosensitive channels (MSL2-10), TRPV1-TRPV5 channels, Piezo channels or their generated site-specific mutants, with or without fusion or conjugation of nanoprobes, are activated by a device providing an external mechanical force or magnetic field, the duration, frequency and intensity of said external mechanical force or magnetic field being adjustable and used for controlled stimulation, molecule introduction or cell death.
